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Abstract
MULTIPLE MYELOMA AND ITS TREATMENT ALTER PERIPHERAL NERVOUS
SYSTEM STRUCTURE AND FUNCTION

Alyssa Katarina Kosturakis, BA
Supervisory Professor: Patrick M. Dougherty, PhD

Peripheral neuropathy is among the most deleterious side effects of frontline
chemotherapeutics used to treat prevalent cancers. Chemotherapy-induced peripheral
neuropathy (CIPN) refers to the collection of symptoms (e.g. pain, paresthesias and
dysesthesias) that develop in distal, glabrous (non-hairy) skin of 20 to 100% of
patients treated with chemotherapy. Peripheral neuropathy negatively impacts quality
of life in cancer patients and survivors, is refractory to treatment, and is the impetus for
dose-reduction and/or cessation of chemotherapy, thereby limiting treatment.
Proteasome inhibitor, bortezomib (Velcade®) is an effective treatment of multiple
myeloma (MM), but often provokes the development of small fiber, sensory, distal
neuropathy in patients. MM is caused by malignancy of plasma cells, which indirectly
compromises multiple organ systems. Therefore, the contribution of underlying
disease versus chemotherapeutic treatment on the development of sensory deficits in
MM patients remains unclear.
This study determined the incidence of subclinical neuropathy in multiple
myeloma patients prior to receiving chemotherapy. MM patients underwent
quantitative sensory testing (QST), which is a non-invasive battery of tests that
provides information about the function of discrete sensory fiber types. Patients
exhibited a high incidence (>80%) of one or more subclinical QST deficits, including
vi

mechanical stimulation, fine tactile discrimination, and warmth detection thresholds,
compared to healthy volunteers. QST also demonstrated enhanced cold pain,
sensorimotor deficits, and higher overall neuropathy scores in MM patients. The
peripheral innervation of the skin was visualized with non-invasive confocal
microscopy and revealed a reduction in the density of touch receptors (Meissner’s
corpuscles) that negatively correlated with performance on the Bumps detection task.
Therefore, MM patients commonly present with sensory and sensorimotor deficits prior
to undergoing treatment, and these deficits appear to be due to disease-related
decreases in peripheral innervation density.
This study subsequently evaluated the efficacy of minocycline in the prevention of
treatment-emergent bortezomib-induced peripheral neuropathy in a double-blind,
placebo-controlled, randomized phase I clinical trial by assessing QST and patient
reports. The placebo group did not show changes in sensory thresholds after
bortezomib treatment, making it difficult to assess the impact of minocycline on
sensory deficits. The minocycline group reported lower rates of tingling that
approached statistical significance (P=0.11). Although statistical significance was not
reached in patient reports of symptoms, several limitations inherent in the study design
and data collection likely impacted the result. Therefore, the use of minocycline to
prevent chemotherapy-induced peripheral neuropathy warrants further investigation in
a follow-up trial.
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1. Introduction
Cancer currently affects over 1.6 million people in the United States and by 2030,
this number is estimated to increase to 2.3 million 1,2. Cancer claims 1 in 4 American
lives and is the second most common cause of death. In less than 20 years, cancer is
expected to be the biggest killer of any single disease 3. However, with increasinglysensitive tests for detecting cancer and the administration of frontline
chemotherapeutic agents, the number of cancer survivors is expected to increase 35%
from 13.7 in 2012 to 18 million by the year 2022 4. Chemotherapeutics are effective in
stopping the progression of cancer because they are often designed to differentially
target and eliminate rapidly dividing cancer cells. Despite their advantages in the
cancer-fighting arena, they are also associated with deleterious side effects (e.g.
anemia, appetite changes, constipation, diarrhea, nausea, vomiting, neurological
changes, infection, fluid retention, fatigue, hair loss, infertility, pain and peripheral
neuropathy) that negatively affect normal cells and structures of the body 5. Given the
potential longevity of biochemical and cellular changes induced by cancer and
chemotherapy, cancer survivors will require a life-time of medical monitoring and
treatment for cancer and/or drug-induced health problems and comorbidities 3. Of the
adverse effects induced by cancer treatment, 20 to 100% of patients (depending on
the study design and agent) develop a condition known as chemotherapy-induced
peripheral neuropathy (CIPN) 6,7. CIPN occurs when peripheral nerves are damaged,
resulting in abnormal sensory function, and pain or loss of motor control. This
condition sometimes leads to chemotherapy dose decrease or cessation, thereby
limiting the efficacy of cancer treatment. The investigations conducted focus on the
1

neuropathy multiple myeloma (MM) patients develop from underlying malignancy as
well as frontline chemotherapeutic agent, Bortezomib (Velcade ®). The following
sections provide a review of the peripheral nervous system, neuropathic pain
conditions, CIPN, MM and treatment agent bortezomib and may be relevant
background information for the reader.
1.1.

Peripheral Nervous System
CIPN is a condition that develops due to insult to the peripheral nervous system

(PNS). The PNS is the network of nerves and ganglia that reside outside of the brain
and spinal cord and is divided into the somatic and autonomic nervous systems. The
autonomic nervous system involuntarily modulates the functioning of the viscera such
as heart rate, respiration rate, perspiration, digestion, sexual arousal and swallowing.
The somatic nervous system is comprised of the nerves that relay sensory and motor
information to and from the central nervous system (CNS). These nerves provide
communication between the skin, sensory organs, joints and all skeletal muscles. The
skin is the largest sensory organ of the body and is home to the endings (both free and
specialized) of primary afferent sensory neurons that transmit stimuli (mechanical,
thermal, and chemical stimuli) from the environment to the CNS. Primary afferents
provide the body with tactile, thermal and nociceptive (actual or potential tissue
damage) information about the external world or the body’s relationship to the external
world (proprioception) 8. Primary afferents are distinct from other types of neurons in
the body because they are pseudo-unipolar. Pseudo-unipolar cell bodies are situated
in between two axons capable of sending information bi-directionally. The axons of
primary afferent neurons form terminals in the skin and transmit sensory information
from a designated area called a receptive field 8. Receptive fields of sensory neurons
2

can vary based on the type of neuron or location in the body. Primary afferent sensory
neurons (including nociceptors) can be classified according to 1. structure and
conduction velocity, 2. modality specificity, 3. threshold of activation and adaptability,
4. receptor expression and cell content.
1.1.1

Structure and Conduction Velocity of Primary Afferents

The structure of primary afferent fibers determines function. There are four broad
classes of primary afferents that have differing axon diameters and myelin thickness,
which determine properties such as conduction velocity. These classes of fibers are
Aα-, Aβ-, Aδ- and C-fibers. Aα-fibers are thickly myelinated and are the largest in
diameter (12-20 µm). Aα-primary afferent sensory neurons are proprioceptors that
innervate skeletal muscles and provide information about limb and body position in
space with conduction velocities of 70-170 m·s-1. Aβ-fibers are myelinated primary
afferent sensory neurons that transmit mechanical information such as light touch.
These have slightly smaller diameters of 6-12 µm and relatively fast conduction
velocities (35-75 m·s-1). Aβ-fibers innervate specialized sensory organs with
characteristic structures allowing detection of the quality (e.g. brief versus long in
duration) of mechanical stimuli (Section 1.2.6). In addition to sensory neurons that
convey information about mechanical stimuli, there are two broad classes of
nociceptors that exist in the skin Aδ- and C-fibers. Aδ-fibers transmit acute or sharp
pain, are thinly myelinated and have conduction velocities of 5-30 m·s-1. C-fibers
encoding dull, burning and diffuse pain are unmyelinated and have slow conduction
velocities (0.5-2 m·s-1) 9. The above characteristics and categories of primary afferent
neurons are not absolute and are an oversimplification of the true physiology. These
characteristics in isolation cannot be used to identify whether a fiber is a nociceptor or
3

not without further evidence of encoding noxious stimuli 10. For example, there is
evidence that a small percentage of Aα- and Aβ-fibers are nociceptive 11.
1.1.2

Modality Specificity of Primary Afferents

The subset of primary afferent neurons responsible for the transmission and
sensory phenomenon of pain are termed nociceptors. Nocicepters are broadly
classified into polymodal, thermal, or mechanical categories 12. Polymodal nociceptors
respond to potentially harmful or harmful mechanical, thermal, and chemical stimuli
and are the most ubiquitous type of nociceptor in the skin. Thermal nociceptors
respond to temperatures associated with tissue damage (greater than 45 °C or less
than 5°C). Mechanical nociceptors respond to harmful or potentially harmful amounts
of pressure applied to the skin 8. It is believed that these nociceptors work in synergy
to produce different qualities of pain 12. For example, pain that is sharp in quality (“first”
pain) and felt acutely is predominately carried by fast-conducting, myelinated Aδ-fibers
while dull, achy pain (“second” pain) is carried by slow-conducting unmyelinated Cfibers 13. Mechanically-insensitive afferents (MIAs) have also been identified that
respond to chemical, but not mechanical stimulation 14. In primates, MIAs make up
approximately 30% of C-fibers and 48% of Aδ-fibers 14. Other subsets of primary
afferents have been characterized in the cat, rabbit, and rodent, and are sensitive to
several modalities or selectively sensitive to different ranges of a certain modality such
as Mechano-cold (C-MC) afferents and Aδ-cold receptors 15,16.
1.1.3

Threshold for Activation and Adaptation of Primary Afferents

Activation thresholds and adaptation are two other characteristics of sensory
neurons. The following characteristics mentioned commonly refer to cutaneous
primary afferents that transmit mechanical stimuli (mechanoreceptors). Low-threshold
4

mechanoreceptors (LTM) respond to low grades of mechanical force (e.g. touch),
whereas high-threshold mechanoreceptors respond to noxious, or potentially noxious
mechanical forces 17. Classically, nociceptors (Aδ- and C-fibers) were thought to have
a high activation threshold, responding only to strong, potentially-damaging stimuli,
whereas Aβ-fibers were thought to be LTM 18. However, low threshold
mechanonociceptors and “silent nociceptors” (nociceptors activated by sustained
nociceptive input rather than immediately following tissue injury) have been identified
19

. Sensory neurons have also been categorized as slowly or rapidly adapting, based

on the encoding of stimulus information. Sensory neurons are tuned to differentially
provide information about the range of magnitude or frequency of the stimuli. Slowly
adapting afferents generate trains of action potentials (APs) in response to long
duration stimuli, while rapidly adapting afferents initially fire APs and then go silent
(Figure 2). Therefore, slowly adapting afferents better encode a maintained stimulus,
in contrast to rapidly adapting afferents, which encode a stimulus that is rapidly
changing 9. Types I and II can be used in conjunction with slowly- and rapidly-adapting
to describe the receptive fields of primary afferents (Figure 2). Type I refers to a small
area where activation thresholds are low, surrounded by an area where activation
thresholds become very high. Type II refers to large receptive fields.
In addition to conduction velocity, structure, threshold for activation, and modality,
the expression of transduction molecules and receptors is responsible for the
properties of individual sensory neurons.
1.1.4

Receptor Expression and Cell Content of Primary Afferents

Primary afferent neurons have heterogeneous cell content and receptor
expression, which contribute to their modality specificity. For example, the polymodal
5

nociceptive C-fibers can be divided into two classes: peptidergic (expressing peptides
such as calcitonin gene-related peptide (CGRP) and substance P) and nonpeptidergic
nociceptors. C-fibers can also be categorized on the basis of receptor expression.
Peptidergic receptors express TrkA (the high affinity nerve growth factor receptor) 20.
Non-peptidergic nociceptors express the P2X3 purine receptor, receptors for glial-cellderived growth factor and the IB4-lectin-binding site 20. Alternatively, primary afferents
can be classified by expression of ion channels. For instance, nociceptors express
voltage-insensitive sodium channels (Nav 1.7 and Nav 1.8) and the non-selective
cationic channel, transient vanilloid receptor 1 (TRPV1). Nociceptors often express
multiple-channel types that vary from one afferent to the next and confer different
properties 10.
In summary, primary afferents, and specifically, nociceptors, are heterogeneous
in their properties, which has made their classification, study and manipulation
challenging.
1.1.5

Skin Morphology and Sensory Transduction

Sensory transduction through primary afferent fibers begins first with a generator
potential whereby a stimulus produces excitation of the membrane. Subsets of
channels located on sensory neurons open in response to stimulation (e.g.
mechanical, temperature, or chemical) producing graded generator potentials, which
depolarize the membrane. If the magnitude of the stimulus reaches threshold, an
action potential is generated proximal to the ending and propagates towards the CNS
9

. The original stimulus is thus converted into an electrical signal that is transmitted to

the spinal cord and brain. Stimuli that are greater than the minimum intensity to
produce an AP are encoded via frequency of action potentials 18. In most neurons the
6

generation of an AP occurs at the junction between the axon and the cell body, called
the axon hillock. However, in sensory neurons the generator potential occurs at the
specialized ending, and when it reaches sufficient magnitude, it initiates an action
potential just proximal to the sensory ending (Figure 1), which is distal to the cell body
located in trigeminal ganglia or dorsal root ganglia (DRG).

7

Figure 1 Mechano-Transduction
Ion channels open in response to mechanical stimulation, producing graded generator
potentials (receptor potentials). If the magnitude of the stimulus reaches threshold, an
action potential is generated proximal to the ending and propagates towards the
central nervous system.
Reprinted from Nature Reviews Neuroscience 12, 139-153, Delmas P, Hao J, RodatDespoix L, Molecular mechanisms of mechanotransduction in mammalian sensory
neurons. Copyright 2011, reprinted with permission from Nature Reviews
Neuroscience.

8

Human skin is composed of epidermis (the most superficial outer layer),
separated by a collagen basement membrane from the deeper-lying dermis. The
dermis forms protrusions that are perpendicular to the skin’s surface called dermal
papillae. Human skin can be hairy or non-hairy (glabrous) 21. Glabrous skin covers the
palms and soles of the feet and has surface features known as epidermal ridges 21.
The epidermal ridges on the fingertip are colloquially referred to as fingerprints 9.
Epidermal ridges are structures that contribute to the pattern of organization of the skin
22

. Glabrous skin is affected during chemotherapy-induced neuropathy and is the

subject of the following sections.
1.1.6

Mechanosensation

Glabrous skin is innervated by encapsulated sensory organs (Merkel disks,
Meissner’s corpuscles, Pacinian corpuscles, and Ruffini endings) as well as free nerve
endings. Merkel disks are oval structures 10-15 µm in diameter located in the basal
layer of the epidermis and are slowly adapting, indicating persistent firing in response
to sustained indentation or pressure on the skin (Figure 2d) 23,24. Merkel disks are lowthreshold mechanoreceptors innervated by Aβ-fibers in a variety of terminal branch
patterns that is suggestive of the complex discharge rates of slowly adapting type I
fibers 9. The evidence suggests that Merkel disks act as mechanical transducers by
releasing glutamate in response to stimulation and generating action potentials in
axons 24.
Ruffini corpuscles are slowly adapting mechanoreceptors identified in hairy
mammalian skin (Figure 2e). Ruffini corpuscles contain a myelinated Aβ-fiber that
ends in a club-like structure. Individual fibers emanate from the club-like structure 25.
Despite their existence in the cat, several experiments suggest that Ruffini corpuscles
9

are absent in glabrous skin of raccoon, primates and humans, therefore, they will not
be further discussed 9.
Meissner’s corpuscles (MCs) are another type of cutaneous
mechanoreceptor with small receptive fields, located in the dermal papillae that line
the epidermal ridges in skin (Figure 2b). They are composed of primary afferent
terminals (multiple Aβ- and at least two types of C-fibers) interdigitated between stacks
of flattened epithelial (laminar) cells and rapidly adapt to 30 to 50 Hz low frequency,
“flutter” stimuli 9. Aβ-afferents can innervate more than one MC. Additionally, each
afferent can innervate different combinations of multiple MCs that are partially
overlapping 22. C-fiber innervation in MCs is both peptidergic and non-peptidergic.
Based on optimal frequency for activation and location in the skin, it is thought that
MCs provide information about an object moving over the skin or conversely, the skin
moving over an object 26.
Pacinian corpuscles are composed of an inner core (formed by specialized
Schwann cells) and an outer core of lamellae layered like the skin of an onion around
Aβ-fibers (Figure 2c) 27. This arrangement may allow for incompressible fluid between
lamellae to press on Aβ-fibers producing a generator potential, and if the stimulus is
large enough, an action potential. Pacinian corpuscles are low-threshold, rapidly
adapting structures that are located deeper than Merkel disks and Meissner’s
corpuscles in the dermis. They have relatively large receptive fields and respond
optimally to high frequency stimuli such as vibration 28.
Aδ- and C-fibers terminate in the dermis and epidermis of the skin as free nerve
endings where they contribute to nociception as well as the detection of mechanical,
thermal, and chemical stimuli as previously mentioned (Figure 2g). A subset of C10

fibers are low-threshold mechanoreceptors that encode light and pleasant touch
(Figure 2f) 29. Although the presence of Aδ- and C-fibers in the epidermis was initially
elusive, these fibers can now be easily detected with an antibody against protein-gene
product 9.5 (PGP 9.5), which is an enzyme located in the cytoplasm of nerves.
In summary, glabrous skin is populated with several structures, including sensory
organs tuned to provide information about specific types of mechanical stimulation and
free nerve endings conveying polymodal stimuli.
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Figure 2 Cutaneous Mechanoreceptors
Glabrous skin contains specialized endings of large myelinated Aβ-fibers (Meissner’s
corpuscles, Pacinian corpuscles, Merkel cell complexes, and Ruffini corpuscles) that
encode different qualities of tactile information depending on whether they are rapidly
adapting (RA) or slowly adapting (SA) and low-threshold (LT) or high-threshold (HT).
Hairy skin contains guard hairs and down hairs innervated by Aβ- and Aδ-fibers,
respectively. A subset of C-fibers convey light touch (C-fiber LTM). C-fibers and Aδfibers also serve as polymodal and mechano-nociceptors.
Reprinted from Nature Reviews Neuroscience 12, 139-153, Delmas P, Hao J, RodatDespoix L, Molecular mechanisms of mechanotransduction in mammalian sensory
neurons. Copyright 2011, reprinted with permission from Nature Reviews
Neuroscience.
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1.1.7

Thermosensation

In addition to detecting mechanical stimuli, mammalian skin is also adept at
sensing temperatures in the range of -10 °C to 60 °C 30. Humans are able to
qualitatively describe four types of thermal stimuli: painful heat, warmth, painful cold
and cool 8. Cultured sensory neurons retain sensitivity to temperature, which has
allowed for electrophysiological investigation of mechanisms of thermosensation 31.
The non-selective cationic channel, TRPV1, is expressed on sensory neurons and
allows depolarization in response to heat ≥42 °C or to the chili pepper derivative,
capsaicin 32. Although it is not the only channel involved in sensing heat, it is
abundantly clear that TRPV1 plays a key role in the sensation of noxious heat.
Knockout of TRPV1 in mice causes both a decrease in reaction to noxious heat as
well as sensitivity to thermal stimulus after tissue injury 33. Another TRPV family
member channel, TRPV2, is activated by heat 52 °C and above and is expressed in
Aδ-nociceptors 34. TRPV3 and TRPV4 are likely to contribute to the perception of
warmth with activations at 27 to 34 °C and 32 to 39 °C, respectively 30. There is also
evidence that other TRP channels contribute to the detection of warmth and heat 30.
Detection of cool stimuli is mediated through TRPM8, which is predominantly
expressed in C-fibers and responds to slight decreases (30-32 °C) in skin temperature
as well as to menthol 35. Although controversial, it is thought that TRPA1 may
contribute to the perception of extreme cold temperatures. TRPA1 expression may be
responsible for the sensitivity of a population of in vitro sensory neurons to
temperatures below 20 °C 36.
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1.2.

Pain, Pain Processing, and Neuropathic Pain
Pain is the disagreeable physical or emotional sensation experienced when the

integrity of tissues and organs of an organism are threatened or damaged 37. Pain is
subjective, meaning that the same injury can cause different magnitudes of discomfort
and be experienced for different lengths of time in different individuals. The difficulty in
quantifying pain in both humans and animals due to a subjective emotional component
of the sensation is one of many challenges to research in the field.
1.2.1 Pain Classifications and Definitions
Nociceptors are specialized cells; a class of primary afferent sensory neurons
capable of encoding and transmitting noxious or potentially noxious stimuli to the CNS
38

. They are composed of an axon located in the periphery, a cell body located in the

dorsal root ganglion, and central terminals, which synapse on the dorsal horn of the
spinal cord 39. Nociceptors are located in skin, muscle, joints, and viscera and after
they are activated by noxious stimuli, they become sensitized either by decreasing
their threshold for activation, or increasing the magnitude of their response 40. This
increase in excitability is believed to underlie the hypersensitivity experienced after
injury. For a brief review of central pain processing see Appendix A.
Nociceptive pain functions to protect tissue from further damage by compelling us
to escape from the harmful stimulus. Three broad classifications of pain exist:
nociceptive, inflammatory, and pathological pain 41. Nociceptive pain is the highintensity, acute pain felt when a noxious stimulus activates nociceptors. Inflammatory
pain results from activation of the immune system following tissue damage or infection.
Acute inflammatory pain is provoked by the recruitment of neutrophils, monocytes, and
macrophages (mature monocytes) to the site of injury that eventually cause swelling,
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redness, aching, and warmth associated with inflammation 42. Prostaglandins and
bradykinin are early mediators of inflammatory pain and increase excitability through
modulation of ion channels on primary afferent sensory neurons. In persistent
inflammatory states other molecules such as cytokines and growth factors induce
upregulation of ion channels, receptors, and inflammatory molecules via gene
transcription 43. Inflammatory pain can be protective to the individual by causing
sensitization of tissues so that further injury is avoided or maladaptive, such as in
conditions such as rheumatoid arthritis.
Although pain is essential for survival, not all pain is protective. Pathological pain
can be chronic or intermittent in nature and is due to dysfunction of the nervous
system. This occurs when pain persists long after initial injury due to dissociation of
the nociceptive stimulus from the pain-processing machinery. In these cases, pain
may even spread distally or proximally from the initial site of injury. Dysfunctional pain
and neuropathic pain are two types of pathological pain. Dysfunctional pain is pain that
arises in the absence of tissue damage or inflammation. Neuropathic pain is defined
as “pain arising as a direct consequence of a lesion or disease affecting the
somatosensory system” 44. Neuropathic pain is debilitating and refractory to
conventional medications and treatments and consequently, is one of the major
challenges clinicians face in treating their patients.
1.2.2 Neuropathic Pain
Neuropathic pain is a type of maladaptive pain produced in response to a
peripheral or CNS injury that persists long after the initial injury and is refractory to
therapy. Many types of injuries and diseases provoke what is broadly termed
neuropathic pain. Though neuropathic conditions are similar, underlying disease is
15

responsible for mechanistic differences and the manifestation of symptoms. For most
patients, neuropathic pain is caused by focal or multifocal lesions of the PNS,
generalized lesions of the PNS (polyneuropathies), lesions of the CNS, or complex
neuropathic disorders 45. Examples of focal or multifocal lesions of the PNS that cause
neuropathic pain include postherpetic neuralgia, phantom limb pain and diabetic
mononeuropathy. Generalized PNS lesions that cause neuropathic pain result from
various conditions, including diabetes mellitus, amyloidosis, alcoholism, HIV-induced
neuropathy, toxic neuropathy (e.g.: chemotherapy-induced), vitamin B deficiency and
hereditary sensory neuropathies 45. Lesions of the CNS that cause neuropathic pain
are spinal cord injury, brain infarction (e.g. of the brainstem and thalamus),
syringomyelia and neurodegenerative diseases such as multiple sclerosis. Complex
neuropathic pain disorders that cause neuropathic pain refer to complex regional pain
syndromes type I and II 45. Therefore, both peripheral and central injury can lead to
neuropathic pain.
1.2.3 Peripheral Mechanisms of Neuropathic Pain
Peripheral nerve injury can lead to neuropathic pain through a change in the
properties of primary afferents and how stimuli are encoded. For instance, primary
afferents become hypersensitive and may fire spontaneously. An upregulation of Nav
1.7, Nav1.8, Nav 1.9 and potentially, Nav 1.3 sodium channels may induce hyperexcitability of nociceptors after injury 46. Nav 1.7 opens in response to small
depolarizations near resting potential; thus modulation of Nav1.7 expression can
dictate the ease of firing an AP. Nav 1.8 is selectively expressed in DRG neurons and
opens to allow depolarization in the absence of voltage change. Nav 1.3 is responsible
for persistent sodium current and is capable of magnifying small depolarizations.
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Nav1.9 opens at hyperpolarized voltages near resting potential and does not
inactivate, thereby potentiating depolarization. Changes in receptor expression on
nociceptors can hence change the firing properties of nociceptors by increasing
excitability and neurally encoding hypersensitivity.
Due to their electrophysiological properties, sodium channels have been linked to
pain in numerous studies. Clinically, mutations in the gene SCN9A that encodes Nav
1.7 have been linked to several of the following disorders: inherited erythromelalgia
and paroxysmal extreme pain disorder patients, display abnormally high pain levels,
as compared to patients who exhibit congenital insensitivity to pain and are unable to
feel pain 47-49. Nav 1.8 mutations are associated with small-fiber painful neuropathy 50.
Pre-clinical studies indicate that Nav 1.9 plays a role in diabetic neuropathic pain and
inflammatory pain 51. In addition to sodium channels, other channels, such as TRPV1,
TRPV4 and TRPM8 are up-regulated in injured nociceptors and contribute to the
development of neuropathic pain 52-54. Other studies have suggested that molecular
changes in undamaged primary afferents accompany injury and play as important a
role in the experience of pain 55.
1.2.4 Central Mechanisms of Neuropathic Pain
As mentioned in Appendix A, central sensitization plays a role in pain and
particularly, in neuropathic pain. The literature implicates a wide array of neurons, ion
channels, signaling pathways, molecules and non-neuronal cells in central
sensitization 56. (See Appendix A for further discussion about central pain processing.)
Damage to peripheral nerves (particularly C-fibers) causes spontaneous activity, which
in turn alters secondary order neurons in the spinal dorsal horn and results in
hyperexcitability via diverse molecular changes. This is accomplished through release
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of the excitatory neurotransmitter, glutamate, as well as peptide neurotransmitters
from primary afferents and hence, an activation of NMDA receptors on second order
neurons. Also, an upregulation of N-type calcium channels pre-synaptically and Nav1.3
channels post-synaptically is believed to underlie this excitability 57,58. In addition to an
up-regulation in the cellular machinery producing excitability, a decrease in inhibitory
mechanisms has also been observed in neuropathic pain conditions 59. This could be
caused by a selective loss of an inhibitory class of neurons, γ-aminobutyric acid
(GABA) neurons, or a loss of the potassium-chloride exporter (KCC2), which causes
cells to become more excitable rather than inhibited in the presence of GABA 59,60.
Research also suggests that changes in descending inhibitory pain pathways may
lead to the promotion rather than the repression of pain 61. Central changes are not
limited to the spinal cord and extend into the brain. Technologies such as functional
magnetic resonance imaging (fMRI), positron emission tomography (PET) and
magneto-encephalography (MEG) have facilitated detection of pain-related changes in
the brain, which will not be further discussed here.
1.2.5 Inflammatory Mechanisms of Neuropathic Pain
Recent evidence also points to an involvement of innate immune mechanisms in
neuropathic pain syndromes, which include an upregulation of diverse inflammatory
mediators 62. Inflammatory substances may be capable of provoking long-lasting pain
through inducing neuroplasticity 62. This can be achieved by binding to respective
receptors, thereby activating downstream signaling molecules capable of entering the
nucleus and influencing gene transcription.
TNF-α is perhaps the most widely studied proinflammatory cytokine in
neuropathic pain and evokes the release of other anti- and pro-inflammatory cytokines.
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Animal models of neuropathic pain wherein the nerve is transected or crushed,
produces demyelination, and degeneration of the distal axon, termed Wallerian
degeneration 63. In response to this type of nerve injury, Schwann cells, mast cells,
endothelial cells, and fibroblasts release TNF-α, which in turn, provokes the release of
other inflammatory mediators. Release of TNF-α is also thought to be responsible for
activating immune mechanisms through the recruitment of phagocytic macrophages to
the site of injury 64. In Wallerian degeneration, non-resident macrophages localize to
the nerve and degrade myelin, contributing to the pain phenotype 65. In addition to
TNF-α, there is strong evidence of the involvement of many other diverse inflammatory
mediators and cytokines in pain. Interleukin-6 (IL-6) plays a complex role in pain. IL-6
is detected in injured primary afferent nerve fibers, DRG, and spinal cord and
peripheral administration of IL-6 causes increased mechanical hypersensitivity 66.
However, IL-6 also plays a role in neuronal survival and regeneration in vitro and in
vivo 66. Interleukin-1 (IL-1) 67 and the chemokine receptors CXCR4, CCR5, CCR4, and
CCR2 are upregulated following nerve injury and facilitate neuropathic pain conditions
68

. Upon binding to respective G-protein coupled receptors (GPCRs), chemokines

potentiate inflammatory and pain states through downstream pathways such as the
mitogen-activated protein kinase system (MAPK) signaling cascade 68. In addition to
central neuronal changes, non-neuronal changes also occur. For example, several
types of glia, including microglia, astrocytes, and satellite glial cells of the DRG are
activated in chronic pain states 69. Thus, neuropathic pain can be initiated due to
peripheral or central injury and potentiated by changes in cellular machinery and
innate immune responses.
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1.3.

Multiple Myeloma Pathophysiology, Diagnosis and Staging
Multiple myeloma patients and their sensory deficits prior to treatment as well as

their development of neuropathic pain post-chemotherapy treatment are the subject of
this thesis. The disease processes of multiple myeloma will be briefly reviewed here.
Multiple myeloma (MM) is a plasma cell neoplasm characterized by uncontrolled
proliferation of plasma cells accompanied by hypercalcemia, renal dysfunction, anemia
and bone lesions (called CRAB criteria) 70. Plasma cells are terminally-differentiated B
lymphocytes that secrete antibodies in response to antigens, thereby protecting the
individual from infection 71. Plasma cells are located in three areas of the body: spleen,
lymph nodes, and bone marrow. These locations allow efficient interaction with
antigens, stimulating release of antibodies, also known as immunoglobulins, into the
bloodstream. B-cell maturation into plasma cells occurs in the bone marrow and is
facilitated by contact with growth factors released from reticular stromal cells.
Chemokines, a family of signaling molecules capable of inducing chemotaxis, are
released from stromal cells and are critical for plasma cell survival 72. When the
transformation of B-cells into plasma cells becomes unregulated, plasma cells
proliferate uncontrollably and overproduce immunoglobulins, which are not adaptive to
fight infection, but rather, produce the co-morbid conditions present in MM patients.
Based on statistics from 2006 to 2010, the number of new cases (adjusted for age)
of MM is projected to be 5.9 per 100,000 men and 3.4 per 100,000 women 73.
Diagnostic criteria for MM are based on high numbers of monoclonal plasma cells,
monoclonal immunoglobulin in serum and/or urine, and bone lesions (apparent in 80%
of patients at diagnosis). Immunoglobulins (antibodies) are released from plasma cells
and are Y-shaped. Immunoglobulins have two paratopes located on each arm of the
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Y-shaped molecules that bind to epitopes on antigens. The Y-structure of an
immunoglobulin is made up of four polypeptide chains: two identical smaller chains
(light chains) linked by disulphide bridges to two identical larger polypeptides, called
heavy chains 74. There are five types of mammalian immunoglobulin heavy chains: α,
δ, ε, ϒ, µ, which distinguish the immunoglobulin isotypes IgA, IgD, IgE, IgG, and IgM,
respectively. In mammals, two light chains exist, termed κ and λ. Similar to MM, other
disorders such as monoclonal gammopathy of undetermined significance (MGUS),
smoldering multiple myeloma, macroglobulinemia, non-Hodgkin lymphoma, essential
cryoglobulinemia, heavy chain disease, and idiopathic cold agglutinin disease, also
present with paraproteinemia, but are all distinct conditions.
Paraproteinemia is the overproduction of paraprotein also known as an abnormal
immunoglobulin light-chain. Patients with MGUS can be distinguished from MM
patients because they have less than 5% monoclonal plasma cells, but no other CRAB
symptoms; however, approximately 1% of MGUS cases will progress to MM 75.
Patients with MGUS or smoldering MM do not require treatment.
Individuals diagnosed with MM must exhibit monoclonal plasma cell proliferation
by bone marrow aspiration and/or bone marrow biopsy. A bone marrow biopsy will
allow the clinician to assess the immunophenotype of the plasma cells as well as the
extent of bone marrow infiltration. A bone marrow aspiration is performed to further
examine the monoclonal cell population with cytogenetics 70. Patient serum and urine
must also be checked for the presence of monoclonal proteins with serum or urine
protein electrophoresis. Detection of IgG or IgA proteins is the most common, but
detection of more than one monoclonal protein is also possible.
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Two staging systems for MM are used to quantify severity of disease and predict
survival: the Durie-Salmon Myeloma Staging System and the International Staging
System. The Durie-Salmon System (Table 1) assesses tumor cell mass, whereas the
International Staging System (Table 2) takes into account β2 Microglobulin (β2M),
which is influenced both by tumor burden and renal function. β2M is the light chain of
the major histocompatibility complex of the cell membrane and high β2M indicates
high proliferation of tumor cells 75. The presence and quantification of other factors
have also been used as prognostic factors. For example, plasmablastic morphology
and chromosome 13 deletions are associated with poor survival 76,77.
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STAGE

CRITERIA

MEASURED MYELOMA
CELL MASS
600 billion/m2

STAGE 1 (low
cell mass)

All of the following:
• Hemoglobin > 10g/dL
• Serum calcium value normal or
<10.5mg/dL
• Bone X-ray: normal bone
structure (scale 0), or solitary
bone plasmacytoma only
• Low M-component production
rates IgG value <5g/dL; IgA
value <3g/dL
• Urine light chain M-component
electrophoresis <4g/24h

STAGE II
(intermediate
cell mass)
STAGE III

Neither Stage I or Stage III

600 to 1200 billion in
whole body

One or more of the following:
• Hemoglobin <8.5g/dL
• Advanced lytic bone lesions
(scale 3)
• High M-component production
rates IgG value >7g/dL, IgA
value >5g/dL
• Bence Jones protein >12g/24h

>1200 billion

Subclassification A: relatively normal renal function
(either A or B)
(serum creatinine value) <2.0 mg/dL
B: abnormal renal function (serum
creatinine value) >2.0 mg/dL

Table 1 Durie-Salmon Staging for Multiple Myeloma 78

23

STAGE

CRITERIA
Serum β2 microglobulin <3.5 mg/L
Serum albumin ≥3.5g/dl

STAGE I

•
•

STAGE II

Neither Stage I or Stage III

STAGE III

•

Serum β2 microglobulin >5.5 mg/L

Table 2 International Staging System for Multiple Myeloma 79
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1.4.

Treatment of Multiple Myeloma

1.4.1 Bortezomib: Clinical Overview
Bortezomib (Millenium Pharmaceuticals Inc. VELCADE®) is a proteasome
inhibitor first approved in 2003 for the treatment of MM in patients after the failure of
three previous therapies 80. It was approved following a successful phase 2 open-label,
nonrandomized trial that showed a 35% complete, partial, or minimal response in MM
patients that had not improved with other agents 81.
Proteasomes breakdown and remove damaged proteins in cells by selectively
catalyzing the degradation of peptides that have been tagged with a small protein,
ubiquitin. Bortezomib reversibly inhibits mammalian proteasome 26S, which disrupts
its ability to cleave and degrade ubiquitin-tagged proteins. The tolerability and efficacy
of bortezomib are due in part to an increased sensitivity of cancerous plasma cells to
the drug as opposed to normal cells to the drug. Though bortezomib was designed as
a proteasome inhibitor, its mechanism for eliminating cancer cells is not fully
understood 82. One possible mechanism of action of bortezomib is that inhibition of
proteasomes causes an accumulation of damaged proteins in the cell that interfere
with cellular function and induce apoptosis 82. Another potential mechanism of the anticancer effects of bortezomib is that through proteasome inhibition it modulates key
cellular pathways, such as the nuclear factor κB (NF-κB) pathway. NF-κB is a family of
transcription factors that modulates immune and inflammatory responses. It also plays
a role in tumorigenesis by inducing growth and proliferation, suppressing apoptosis,
and enhancing tumor cell invasiveness and metastasis. Inhibitor of nuclear factor κB
(IκB) is a protein that binds NF-κB in the cytoplasm and inhibits it from travelling to the
nucleus and initiating transcription of growth factors 82. Normally, proteasome 26S
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cleaves IκB, however, administration of bortezomib blocks proteasomal degradation of
IκB. IκB is then able to bind and inhibit NF-κB, thereby blocking cell survival activities
in tumor cells82. Bortezomib may also induce apoptosis in tumor cells by promoting
mitochondrial Ca2+ dysregulation, thereby activating pro-apoptotic mediators: caspase
3, 8, 9 and 12 83. Although bortezomib affects several key cellular pathways,
interference with these pathways likely has numerous downstream effects, which
remain to be characterized. Regardless of mechanism, bortezomib shows impressive
partial and complete response rates when administered as a single agent 81.
Bortezomib is typically administered at a dose of 1.3 mg/m2 or 1.0 mg/m2 by
intravenous bolus or subcutaneously on days 1, 4, 8, and 11 of a 21-day cycle.
Patients receive multiple cycles depending on individual response rate. The most
common adverse events associated with bortezomib are fatigue, thrombocytopenia,
gastrointestinal issues, and sensory neuropathy 81,84-86. In an initial study, 34% of
patients reported new or worsening symptoms of neuropathy with bortezomib 81.
Subsequent trials using bortezomib as a single-agent induction therapy for multiple
myeloma reported treatment-emergent sensory neuropathy in 64% of patients 85. In an
analysis of two bortezomib phase II studies with 256 enrolled patients, 90 patients
experienced treatment-emergent neuropathy, 5% of patients discontinued treatment
due to neuropathic symptoms, and 12% of patients received a dose reduction due to
peripheral neuropathy 85. Bortezomib-induced neuropathy (BIPN) is typically sensory,
although motor neuropathy has also been reported 87. The incidence of peripheral
neuropathy varies depending on the trial, grading scales, and detection methods of
neuropathy. To increase the efficacy of bortezomib, polymodal therapy has been
implemented; bortezomib has been combined with several other agents including
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dexamethasone alone, dexamethasone and thalidomide, prednisone alone, melphalan
and prednisone and lenalidomide. Richardson et al. reported that multiple therapies do
not increase the incidence of reported neuropathy 86.
Neuropathy is the most clinically relevant side-effect of bortezomib. Due to the
prevalence of neuropathy, BIPN provokes dose reduction and/or discontinuation of
therapy. The incidence of neuropathy typically increases as patients receive more
cycles of chemotherapy and cumulative dose of the drug increases87. Furthermore, the
most significant risk factor for the development of neuropathy is a previous history of
neuropathy 88. Fortunately, BIPN may be reversible: 60% of cases return to baseline
levels of neuropathy within a median of 5.7 months. However, other studies still
observe neuropathy at a year following treatment 88,89. The etiology and mechanisms
underlying BIPN are poorly understood. BIPN is debilitating and treatment-limiting and
requires further investigation in animal models.
1.4.2 Bortezomib-Induced Neuropathy: Pre-Clinical Studies
Animal studies have attempted to characterize the pathophysiology of BIPN. Rats
treated with bortezomib at a clinically-equivalent dose display neurophysiological and
histopathological differences compared to control animals. Sensory nerve conduction
velocity is significantly reduced and the sciatic nerve in these rats exhibits damaged
Schwann cells and degeneration of myelin, though recovery was observed after 4
weeks. The dorsal root ganglions (DRGs) of these animals showed increased
recruitment of satellite cells 90. Bortezomib-treated animals also have an abundance of
ubiquitin-tagged proteins in DRG neurons and signs of abnormal transcription and
translation, which likely contributes to sensory neuron dysfunction 91. Taken together,
these data show that bortezomib damages peripheral nerves and their cell bodies, yet
27

the underlying pathways leading to this destruction are unclear. Despite carefully
conducted animal studies, the mechanism by which bortezomib induces neuropathy
remains elusive.
1.4.3 Other Therapies
Thalidomide is another chemotherapeutic agent used to treat MM. Thalidomide
modulates the immune system to increase natural killer cells and T-cells, inhibiting
cytokine production and angiogenesis and inducing apoptosis. Potential mechanisms
of thalidomide-induced neuropathy include the down regulation of tumor necrosis
factor-α (TNF-α), which induces demyelination and Wallerian degeneration or direct
damage of the DRG 92. Symptoms include dose-dependent abnormalities in the form
of distal paresthesias or dysesthesias and possible weakness. Aside from
chemotherapy, autologous stem-cell therapy is usually considered as an option for the
treatment of MM and may prolong life if a complete response is attained 93. The
severity of neuropathy induced by chemotherapeutic agents in individual patients
dictates the future dose that can be administered. In order to quantify neuropathy,
several grading scales have been implemented.
1.4.4 Overview CIPN Symptoms and Grading Scales
Primary afferent neurons and their cell bodies located in the DRG are particularly
vulnerable to the toxic effects of chemotherapy because they do not have a protective
blood-brain barrier like the CNS. Without the blood-brain barrier, substances in the
blood can freely exchange across the walls of DRG and affect primary afferents 92. In
cancer patients this produces an array of sensory disturbances (e.g. numbness,
tingling, burning, or dysesthesias) broadly known as chemotherapy-induced peripheral
neuropathy (CIPN) that affect the hands and feet in a glove and stocking distribution
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94

. Patients typically present with symptoms consistent with CIPN weeks or months

after beginning chemotherapy treatment. Several chemotherapies are notorious for
causing CIPN, however the presentation and onset of symptoms varies depending on
the drug, perhaps due to mechanistic differences. CIPN is generally thought to
improve after chemotherapy treatment has ended; however, the platin family of
compounds (e.g. oxaliplatin, carboplatin and cisplatin) is known to cause worsening of
symptoms after treatment has been stopped (a phenomenon known as “coasting”) 92.
Bortezomib-treated patients most commonly describe their sensory symptoms as
tingling (paresthesia), hypersensitivity (hyperesthesia), numbness (hypoesthesia),
abnormal sense of touch (dysesthesia), burning, or pain and their motor symptoms as
weakness 95. Although much less common, some chemotherapies such as
bortezomib, may also affect the autonomic nervous system causing orthostatic
hypotension, sex organ dysfunction and constipation. For a complete discussion of
different chemotherapeutics, the potential mechanisms by which they induce
neuropathy, and the quality of neuropathic symptoms induced, see review articles
92,96,97

.

CIPN is challenging to quantify because of the subjectivity of patient and provider
reports. Hence several grading systems have been developed in an effort to increase
objectivity. Historically, three different grading scales of peripheral neuropathy have
been implemented that categorize neuropathy numerically from Grade 0 to Grade 4.
These include the World Health Organization (WHO) Common Toxicity Criteria for
Peripheral Neuropathy, National Cancer Institute (NCI) Common Toxicity Criteria, and
the Eastern Cooperative Oncology Group (ECOG) Grading Scale for CIPN 98.
According to the WHO rating scale, a Grade 0 corresponds to no symptoms of
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neuropathy, Grade 1 corresponds to paresthesias (a tingling, tickling or prickling
sensation) and/or decreased tendon reflexes, Grade 2 corresponds to severe
paresthesias and/or mild weakness, Grade 3 corresponds to intolerable paresthesias
and/or marked motor loss and Grade 4 corresponds to paralysis. NCI and ECOG
ratings make slight modifications to the WHO rating system. The Total Neuropathy
Score (TNS) is slightly different in that it rates patients with a cumulative score ranging
from 0 to 32 based on deep tendon reflexes, pin sensation, vibration sense, nerve
conduction, and subjective self-report of symptoms from the patient 99.
Another sensitive, yet non-invasive method of assessing the extent of neuropathy
is quantitative sensory testing (QST). QST is a battery of testing administered to
patients that measures sensory function in several different modalities and assesses
the function of discrete fiber types. Touch detection thresholds measure Aβ-function,
temperature thresholds measure function of different populations of Aδ- and C-fibers,
and sharp detection thresholds measure Aδ-fiber function. A 2010 study using QST
on 1236 neuropathic pain patients in a multi-center study found both loss and gain of
sensory function in patients as compared to healthy controls as well as a high degree
of heterogeneity between patients in the modalities tested 100. This emphasizes the
complex array of sensory phenotypes attributable to neuropathic pain syndromes that
can be differentiated by testing discrete fiber types using QST.
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1.5.

Hypothesis and Specific Aims
Peripheral neuropathy as a consequence of chemotherapy is a common cause of

dose reduction or discontinuation of therapy in cancer patients, thereby limiting
treatment and negatively impacting survival. In both human and animal models,
treatment with chemotherapeutics is associated with the development of sensory
neuropathy and a distal loss of peripheral nerve fibers in glabrous skin 6. However, it is
unclear whether pre-existing subclinical deficits predispose patients to developing
chemotherapy-induced peripheral neuropathy and whether pre-clinical therapies
utilized in clinical trials will successfully treat CIPN. These studies address the
following hypotheses:

Hypothesis 1: Multiple myeloma patients exhibit decreases in peripheral innervation
and sensory changes that can be quantified prior to chemotherapy treatment.
Specific Aim 1.1: Use QST to compare sensory thresholds of multiple myeloma
patients to age-and-sex matched healthy volunteers.
Rationale: Colorectal cancer patients prior to induction therapy display
sensory deficits 153. Ten percent of MM patients present with overt
clinical neuropathy prior to chemotherapy treatment. Sensory thresholds
of MM patients that are different from those of healthy volunteers may
indicate deficits in the fiber types mediating those modalities. Sub-types
of fibers with subclinical deficits may be particularly vulnerable to the
effects of bortezomib. A recently published study suggests that preexisting sensory deficits in MM patients are associated with patient
reports of pain and numbness during treatment 107. In addition, research
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suggests that pre-existing neuropathy puts patients at risk for developing
treatment-emergent neuropathy.
Specific Aim 1.2: Determine if MM patients exhibit decreases in peripheral
innervation. Correlate densities of touch receptors (Meissner’s corpuscles) to
performance on fine tactile discrimination tasks in MM patients and volunteers
using non-invasive confocal microscopy .
Rationale: Pre-clinical studies in animals and biopsies in patients indicate that
sensory neuropathy is and neuropathic-like symptoms are associated with a
dearth of nerve fibers in distal glabrous skin.

In addition to subclinical deficits likely caused by disease-related processes,
studies demonstrate that chemotherapy administration induces or exacerbates
sensory deficits. The development and application of preventative treatments would be
useful to avoid this detrimental and dose-limiting side effect. Minocycline is a
tetracycline antibiotic with neuroprotective properties that reduces hypersensitivity and
spares primary afferent fibers in rodent models of CIPN.

Hypothesis 2: Oral minocycline administered with the chemotherapeutic agent,
bortezomib, will prevent sensory neuropathy induced by bortezomib and decrease
patient-reported outcomes of neuropathy.
Specific Aim 2.1: Assess the efficacy of 200 mg/day oral minocycline HCL in
preventing bortezomib-induced neuropathic pain in multiple myeloma patients by
measuring sensory thresholds using QST and assessing patient reports of
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tingling and numbness in a randomized, double-blind placebo-controlled, clinical
trial.
Rationale: Minocycline has neuroprotective properties in preclinical
studies investigating both spinal cord injury-induced and chemotherapyinduced neuropathic pain.
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2. Subclinical peripheral neuropathy in multiple myeloma patients prior to
chemotherapy is correlated with decreased fingertip innervation density

Chapter 2 is adapted from the publication Kosturakis et al., Subclinical peripheral
neuropathy in multiple myeloma patients prior to chemotherapy is correlated with
decreased fingertip innervation density, Journal of Clinical Oncology (Accepted).

2.1.

Introduction
The goal of this study was to quantify sensory deficits MM patients exhibit prior to

receiving chemotherapy to address Hypothesis 1 of this thesis.
MM patients typically seek care with signs of renal insufficiency, anemia and bone
lesions 101. Bone lesions occur due to bone resorption and include lytic abnormalities
or diffuse osteopenia, both of which lead to increased calcium in extracellular fluid and
may cause hypercalcemia. Renal failure can occur due to non-paraprotein-related
causes (e.g., hypercalcemia, nephrotoxic drugs, dehydration, hyperviscosity, and
myeloma cell infiltration) or paraprotein-related causes (e.g., cast nephropathy,
amyloidosis, light chain deposit disease or Fanconi syndrome). Anemia in MM patients
is usually caused by treatment with chemotherapeutics, deficient production of
erythropoietin, and tumor infiltration of the bone marrow.
Overt neurological complications may also occur from tumor invasion into the
vertebral space that compresses the spinal cord, cranial nerves or nerve roots,
intracranial invasion of tumor and metabolic derangements 102,103. Clinically significant
peripheral neuropathy without clear etiology prior to treatment is reported in 5 to 20%
of patients 89,102,104,105. The incidence of CIPN affects approximately 70% of patients,
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depending on the therapeutic agent 104,105. In fact, the development of treatmentemergent peripheral neuropathy is the most common cause of dose reduction or
discontinuation of chemotherapy, potentially impacting survival 86,106. The proteasome
inhibitor bortezomib (Velcade®) is a common treatment for MM and is associated with
high rates of peripheral neuropathy that may become chronic and refractory to
treatment 89,105.
Given the potential profound impact of neurological complications on disease
treatment and quality of life, interest has centered on identifying means to avoid the
occurrence of treatment-related neuropathy in MM patients. QST are a series of noninvasive measures capable of detecting deficiencies in sensory nerve fiber function. In
one recently published study, the presence of subclinical sensory deficits in MM
patients was suggested as predictive of the development of CIPN 107. While patients
with pre-treatment impairments in sharpness detection (a test assessing Aδ-fiber
function) were at decreased risk for developing CIPN, baseline impairments in warmth
detection (a test assessing C-fiber function), were associated with more severe pain
and numbness after chemotherapy treatment 107.
Biopsies collected from glabrous skin sites in patients treated with
chemotherapy show decreases in peripheral innervation, including loss of both
intraepidemal nerve fibers and Meissner’s corpuscles (MCs) 89. MCs are rapidly
adapting cutaneous receptors that detect tactile stimuli moving at frequencies of 30 to
50 Hz 9. This sensation can be described as “flutter.” Non-invasive in vivo confocal
microscopy is a novel imaging technique for visualizing the epidermis and superficial
dermis that allows clear identification of MCs within dermal papillae. MC density
assessed by in vivo confocal microscopy is well correlated to MC density assessed by
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skin biopsy 108. The goals of this study were to quantify the sensory changes in MM
patients prior to chemotherapy treatment, thereby determining the prevalence of
subclinical peripheral neuropathy and to correlate impairments in touch thresholds with
decreased peripheral innervation density assessed with in vivo laser reflectance
confocal microscopy.

2.2.

Subjects and Methods
2.2.1 Patients and Volunteers
Twenty-seven patients with no previous symptoms, complaints of peripheral

neuropathy or clear risk factors for neuropathy were recruited into this study through
the Multiple Myeloma Clinic at The University of Texas MD Anderson Cancer Center.
A group of 30 age- and sex-matched healthy volunteers recruited from the institution
staff provided comparative data. All subjects provided informed consent to participate
in the research protocols that had been reviewed and approved by the Institutional
Review Board of the MD Anderson Cancer Center.
2.2.2 Quantitative Sensory Analysis
Quantitative sensory analysis was performed as previously described 89,108,109. Based
on the distribution of sensory disturbances that have been documented in CIPN 89,109,
three areas, the fingertip, thenar eminence (palm) and volar surface of the forearm
(forearm), were selected for sensory testing. The dermatomes that correspond to the
fingertip, thenar eminence and volar forearm are C6, C6, and either C6 or C8,
respectively 110.
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2.2.3 Touch Detection Thresholds and Grooved Pegboard Test
Touch detection thresholds were determined using von Frey monofilaments
(Semmes-Weinstein) (Figure 3) in an up/down manner 89,109. Starting with a bending
force of 0.02 grams, each filament was applied to the skin for approximately 1 second
in each of the three test sites mentioned above. During this test, subjects were
instructed to close their eyes or look away so that they did not see the application of
the filament. If the subject failed to detect the stimulus, the next higher force was
applied to the same location. When the subject detected the presence of the stimulus,
the next lower force was administered. This procedure continued until the same
filament was detected for three applications, and the associated force was considered
the touch detection threshold.
To assess fine touch discrimination, a second method based on the detection of
minute elevations (bumps detection) on a smooth surface was employed 89,111. The
bumps device consists of three etched glass plates (11.5 cm x 15 cm), each of which
contains twelve 1.5 x 1.5 inch squares (Figure 4). Within each square are 5 flat circles,
each of a different color. Located over one of the circles within each square is a bump
that is 550 µm in diameter. Bumps on plate 1 vary from 2.5 to 8.0 µm in height, bumps
on plate 2 vary from 8.5 to 14.0µm in height, and bumps on plate 3 range from 14.5 to
26 µm in height. Participants began each session using bumps that ranged from 8.5 to
14 µm. Subjects were instructed to use the index finger of the dominant hand to
explore the five circles within each square. Patients were unable to see the location of
the bump and reported to the examiner which color they perceived the bump to be
located on. If participants could correctly identify the location of bumps on plate 2, they
progressed to plate 1 (2.5 to 8 um). Patients unable to detect the location of bumps on
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plate 2 were presented with plate 3 (14.5 to 26um). The Bumps detection threshold
was determined to be the smallest bump correctly identified in sequence to the next
two higher bumps 111.
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Figure 3 Touch Detection Assessed With Von Frey Monofilaments
Monofilaments
nofilaments based on the Semmes
Semmes-Weinstein monofilament set.. When pressed
against the skin in sequence (from smallest to largest), these filaments apply an
approximately logarithmic scale of actual force and a linear scale of perceived
intensity.

Figure 4 Fine Tactile Discrimination Asses
Assessed With the Bumps Detection Plate
A bump of known size ranging from 2.5 to 26 um was present in one of the five colored
circles in each square. Subjects reported the color that corresponded to the location of
the bump.
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Manual dexterity was assessed with the grooved pegboard test (Figure 5) 112.
Patients were instructed to fill a 5 × 5 slotted pegboard in an ordered fashion, either
across rows or down columns. The time a subject took to complete the board was
measured for both dominant and non-dominant hands. A faster time indicated greater
dexterity 112.
2.2.4 Sharpness Detection Threshold
The ability to detect sharpness was determined using weighted needle devices
of 8, 10, 16, 20, 30, 32, 64, and 128g (Figure 6) 113. Each stimulus was applied for 1
second in ascending order using a modified Marstock method 114. The subjects were
instructed to state whether the sensation produced by each stimulus was that of touch,
pressure, sharpness, or pain. The sharpness detection threshold was the weight
corresponding to the sensation of ‘‘sharp’’ or ‘‘painful.’’ Sharpness was measured in
three separate trials separated by an average interval of 30 to 90 seconds. The
average of three trials was the recorded sharpness detection threshold.

Figure 5 Manual Dexterity Assessed with Grooved Pegboard Test
A grooved pegboard with irregularly shaped slots oriented at different angles and
pegs.
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Figure 6 Weighted, Blunted Needle Assessed Sharpness Detection
A blunted needle and attached weight were inserted into a plastic tube. The needle
was applied to the test site and freely moved in the barrel of the plastic tube so that the
associated weight was applied. Patients were instructed to report whether they
perceived touch, pressure, sharp or pain. End points for sharpness detection were
reports of pain or sharp.
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2.2.5 Heat and Cold Detection Thresholds
Warmth detection and heat pain threshold were determined by applying heat
stimuli to the testing site with a 3.6 by 3.6-cm Peltier probe (Figure 7) 89,109. The
baseline temperature of the probe was set at 32°C and the temperature increased at a
rate of 0.30°C/second. Subjects signaled when the probe was first perceived as warm
and then, painful. The trial was subsequently terminated and the probe returned to
baseline temperature. The final warmth detection and heat pain threshold for each site
was defined as the mean of three trials that were separated by an average of 30 to 90
seconds. If a subject failed to perceive warmth or heat pain, the cutoff temperature of
52°C was recorded as the default.
The threshold to detect cooling of the skin (cool threshold) and then cold pain
(cold threshold) was determined as described above, except that the temperature
decreased at a rate of 0.50°C per second. If a subject failed to perceive cold pain, the
cutoff of 3°C was recorded as the default value.
2.2.6 Skin Temperature
Skin temperature was measured using a radiometer placed gently against the skin for
approximately 2 seconds (Figure 8).

42

Figure 7 Peltier Thermode Probe Assessed Temperature Thresholds
A thermode was applied to the testing site and increased or decreased in temperature
to assess warm detection, heat pain, cool detection, and cold pain.

.

Figure 8 Skin Temperature Radiometer
Skin temperature at the testing sites was assessed using a radiometer
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2.2.7 Imaging and Meissner’s Corpuscle Quantification
In vivo confocal imaging was performed on the skin of 12 patients and 10 healthy
controls using Lucid Vivascope 1500 as previously described (Figure 9) 108. The
microscope was centered on the tip of the fifth digit over a plastic ring and produced
an image with a 2.0 mm by 2.0 mm field of view. Skin architecture was assessed using
a stack of four images with a vertical resolution of 3 to 5 µm at different depths (z
plane = 20 µm). MCs were quantified at the depth that was most easily visualized by a
research assistant blinded to the study group. Images that were 4.0 mm2 were divided
into four quadrants and MCs were quantified on one randomly chosen quadrant.
Meissner’s corpuscles were identified as round light-colored structures 40 to 60 µm in
diameter located in dermal papillae as previously described 108.
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Figure 9 Lucid Vivascope 1500 Non-Invasive Confocal Scanner
The lens was attached to the site of interest and the non-invasive confocal scanner
obtained a series of images of different layers of skin. The scanner produced a stack
of four 2.0 mm x 2.0 mm images taken at depths that varied by 20 µm. The density of
the touch receptors, Meissner’s corpuscles, were visualized as round, light colored
structures and quantified on one of the images.
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2.2.8 Statistical Analysis
Comparisons of sensory and sensorimotor thresholds were performed between
volunteers and patients by first, evaluating for normality using the Shapiro-Wilk test
and then, using the non-parametric Wilcoxon signed-rank test. Results are reported as
mean ± standard error of the mean. Correlations were performed with the nonparametric Spearman’s Rank-Order correlation. For every comparison, P<0.05 was
considered significant.

2.3.

Results
2.3.1 Study group
Patient characteristics are presented in Table 3. None of the patients had a

history of chemotherapy treatment, AIDS, diabetes or irradiation exposure that might
have contributed to the development of neuropathy. All QSTs on patients were
collected before chemotherapy had been initiated. Healthy volunteers had no
exposure to equipment or testing procedures prior to undergoing QST. QST and scans
were collected by a study coordinator who did not participate in the data analysis.
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Patient demographics (n=27)
Characteristic
Age-years, mean (SD)
Gender
Male
Female
Race
White
Black
Hispanic
International Staging System
Stage I
Stage II
Stage III
Amyloidosis
Yes
No
SD= Standard Deviation
Table 3 Patient Demographics
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n
60.4
(9.7)

%

13
14

48.1
51.9

20
5
2

74.1
18.5
7.4

11
10
6

40.7
37.0
22.3

3
24

11.1
88.9

2.3.2 Touch Detection Thresholds and Grooved Pegboard Times
Touch detection thresholds, a gauge of Aβ-fiber function 115-117 were obtained
using von Frey monofilaments. Touch detection was higher (implying impairment) at
the thenar eminence and the volar forearm, but not the fingertip, in the MM patients as
compared to healthy volunteers (Figure 10A). Specifically, the touch detection
thresholds in the palm and the forearm were 0.26±0.03g and 0.32±0.04g in the
volunteers, whereas the respective values for MM patients at these sites were
0.52±0.07g (P<0.01) and 0.56±0.10g (P<0.05). Importantly, patients exhibited
significant impairment in Bumps detection (Figure 10B). The mean Bumps detection
threshold for MM patients was 6.30±0.86 µm but only 3.37±0.38 µm for the volunteers
(P<0.01). Thus, the Bumps test was more sensitive than von Frey monofilament in
detecting impaired touch sensation at the fingertip.
Patients also showed a pronounced impairment in the sensorimotor slotted
pegboard task (Figure 10C). The completion times for the dominant hand were
69.36±2.56 seconds for volunteers and 90.63±6.60 seconds for patients; (P<0.01).
The respective values for the non-dominant hand were 74.30±3.08 seconds and
86.33±3.20 seconds; (P<0.01). Combined, these findings indicate that MM patients
with no outward signs or symptoms of neuropathy have impaired Aβ-fiber function and
dexterity prior to chemotherapy.
2.3.3 Sharpness Detection Thresholds
The results of the sharpness detection task are shown in Figure 10D.
Sharpness detection is a measure of Aδ-fiber function. No significant deficits in
sharpness detection were observed between the patient and the volunteer groups,
suggesting that MM does not alter this subset of Aδ-fibers.
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Figure 10 MM Patients Show Differences in Touch Detection and Peg Board
Performance, But Not Sharpness Detection
To assess mechanosensation, touch and bumps detection tests were employed
(A&B). Subjects completed the grooved pegboard as an assessment of sensorimotor
performance (C). Weighted-blunted needles assessed the ability to detect sharp (D).
The bar graphs show the mean values (and standard errors) of sensory tests for
multiple myeloma patients (black bars) and healthy volunteers (gray bars). (A) Touch
detection (g) determined with von Frey monofilaments measured Aβ-fiber function. (B)
Dominant and non-dominant hands in completing the slotted pegboard task (s)
measured sensorimotor function. (C) Bumps detection (µm) was performed using the
index finger of the dominant hand and measured fine tactile discrimination. (D)
Sharpness detection threshold (g) measured Aδ-fiber function.
*= P<0.05, **= P <0.01
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2.3.4 Skin Temperature and Thermal Detection Thresholds
Baseline skin temperature was significantly higher at the thenar eminence, but
not at the other test sites (patients 34.56±0.24 oC vs. 33.66±0.35 oC) (P<0.05) (Figure
11A). Figure 11 also shows differences between the groups in detection thresholds for
heat and cold. The MM patient group showed significantly higher (P<0.05) thresholds
for warmth detection across all three test sites (patients—fingertip: 39.45±0.38 oC
(P<0.01), thenar eminence:37.83±0.29 oC (P<0.01), volar forearm: 37.78±0.34 oC
(P<0.05) vs. volunteers—fingertip: 37.90±0.45 oC, thenar eminence: 36.72±0.26 oC,
volar forearm: 36.54±0.40 oC) (Figure 11B). Heat pain threshold was similar between
groups at all sites. Heat threshold at the fingertip occurred at the expected range of 45
to 47oC. Heat thresholds were slightly lower at the thenar eminence and volar forearm
of both MM patients and healthy volunteers due to inherent differences in the
sensitivity at the testing site (Figure 11B). The threshold to detect innocuous cool
sensation was comparable between the patients and volunteers (Figure 11C).
However, cold pain thresholds were significantly elevated at the thenar eminence and
volar forearm of MM patients. Mean cold pain thresholds for patients vs. volunteers
were 14.67±1.55 oC vs. 7.33±1.10 oC at the thenar eminence (P<0.001), and
13.31±1.62oC vs. 7.46±1.04oC at the volar forearm (P<0.01) (Figure 11C).
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Figure 11 MM Patients Show
Differences in Skin Temperature
and Thermal Detection Thresholds
The bar graphs show the mean (and
standard error) (A) baseline skin
temperature and (B&C) thermal
detection thresholds (oC) for MM
patient (black bars) and volunteer
(gray bars) groups. (B) Warm
detection (left hand bar group) and
heat pain threshold (right hand bar
group). (C) Cool detection (left hand
bar group) and cold pain threshold
(right hand bar group).
*= P<0.05, **=P<0.01 , *** = P<0.001
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2.3.5 General Neuropathy Score
An overall neuropathy score was generated for each patient and volunteer by
summing the number of observations for each subject where any of the measures
listed above were greater than 2 standard deviations from the mean of the volunteer
dataset. In total, 22 of 27 (81.5%) patients vs. 10 of 30 (33.3%) of healthy volunteers
had at least one out-of-range measure (Figure 12). Patients had a mean of 2.48 ± 0.34
observations of out of range measures. In contrast, volunteers had a mean 0.60 ± 0.19
out-of-range observations (P < 0.0001) (Figure 12).
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Figure 12 Greater Numbers of MM Patients Displayed Out-of-Range Measures
Compared to Volunteers
The scatter and line plot shows the number of out-of-range measures (measures more
than 2SD outside the mean) present in individual subjects (cumulative observations).
(open symbols: healthy volunteers; solid symbols: patients). The inset bar graph
shows the mean out-of-range QST observations for volunteers (gray bar) and MM
patients (black bar).
****= P < 0.0001
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2.3.6 Quantification of Meissner’s Corpuscles
A subset of thirteen MM patients and ten healthy volunteers underwent non-invasive
confocal imaging of the fingertip of the fifth digit (Figure 13A). Two MM patients
underwent one repeat scan three months after the first scan, for a total of 15 patient
images that were quantified. To correlate Bumps score with MC density, Bumps
detection was performed in this patient subset. Patients had a significantly higher
mean Bumps score than healthy controls (5.73 ± 0.78 µm and 3.50 ± 0.53 µm
respectively, P<0.05). Confocal images showed that patients had a decreased mean
density of MCs as compared to controls (2.63 ± 0.28 MCs /mm2 vs. 4.88 ± 0.62
MCs/mm2, P<0.01) (Figure 13B). The Spearman’s Rank-Order correlation was used
to assess the linear relationship between MC density and Bumps detection threshold.
As Bumps detection threshold increased, MC density decreased (ρ= -0.69, P<0.001)
(Figure 13C).

54

Figure 13 Inverse Correlation Between Meissner’s Corpuscle Density and Touch
Detection
(A) Representative healthy volunteer and patient images of 1.0 X 1.0 mm in vivo laser
reflectance confocal micrograph. In the volunteer image, numerous Meissner’s
corpuscles (MCs) can be seen as white orb shaped structures sitting in the base of the
dermal papillae (dark circles). Several MCs are indicated by red arrows. Unfilled
arrows demarcate several of many dermal papillae missing MCs. One MC is visible in
the patient image. Light color bands are the elevated fingertip ridges. (B) Mean (and
standard error) Bumps detection score and MC density for a subset of MM patients
(black bar) and healthy volunteers (gray bar). (C) The inverse correlation between
Bumps detection threshold and MC density in patients and volunteers is illustrated in
the scatter plot. As Bumps detection threshold increases, MC density decreases
(overall, ρ=0.69, P <0.001).
*= P <0.05, **=P<0.01
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2.4.

Discussion
The results shown here indicate that subclinical sensory dysfunction consistent

with early onset neuropathy is highly prevalent in patients with MM prior to
chemotherapy treatment. Impairments were observed in low-threshold
mechanosensation, sensorimotor tasks and in thermal detection, consistent with
dysfunction in Aβ-, Aδ- and C-primary afferent fibers 118-121. MC density on confocal
scans was similar to MC density quantified in skin biopsies, which suggests that in vivo
confocal microscopy is a non-invasive, quantitative method to assess MC density 108.
Patients showed decreased densities of MCs by confocal imaging that were negatively
correlated with their ability to detect small bumps in the Bumps detection test. These
data suggests that a decrease in tactile sensitivity is well correlated with MC density as
visualized by in vivo confocal imaging and is consistent with studies comparing Bumps
threshold to MC density quantified in skin biopsy 118. Taken together, this suggests
that nervous system complications are more prevalent in chemotherapy-naïve MM
patients than previously appreciated.
Neurological complications in MM are multifaceted. The most common
neurologic involvement is radicular pain due to spinal cord or nerve root compression
following lytic bone lesions 121. Consistent with the findings reported here,
electrophysiological assessments prior to therapy reveal that roughly one third of
newly diagnosed MM patients have evidence of peripheral nerve involvement 121,122.
The increased incidence of patients identified with subclinical neuropathy here is
simply due to the higher sensitivity for quantitative sensory tests to reveal nerve fiber
dysfunction than electrophysiological methods. The important implication in this work
is that pre-treatment sensory deficits likely predispose patients to develop drug56

induced neuropathy because CIPN occurs more frequently and manifests more
severely in patients with existing neuropathy 106,107,123.
Neuropathy prior to treatment in MM patients implicates mechanisms based on
individual and disease-related factors. In part, the patient cohort affected by MM is
largely an elderly patient population diagnosed at a median age of 66 124. Advanced
age is associated with a decline in innervation density (e.g. density of MCs) 125,126. This
factor was accounted for with an age-match of the non-patient volunteers, indicating
that a disease-related process is linked with a decrease in MCs in MM patients.
Despite having a similar age, healthy volunteers had significantly more distal fingertip
innervation than patient counterparts evidenced by higher MC density. MC density
visualized on confocal scans was correlated with fine tactile discrimination. Of note,
healthy volunteers with varying numbers of MCs were able to discern the smallest
bump during the Bumps test. Thus, individuals with the highest density of MCs may
have been able to detect bumps smaller than 2.5 µm (the smallest bump used in the
QST) creating a floor effect in the data and a dampened correlation between MCs and
tactile discrimination. Despite the presence of a floor effect, individuals who performed
worse on the tactile discrimination test had lower densities of MCs and more sensory
abnormalities consistent with sensory neuropathy. These data suggests that in vivo
confocal imaging may be a novel and sensitive method for early detection of sensory
deficits consistent with neuropathy. Although this technology is a potentially useful tool
to quantify peripheral innervation, several limitations of this technology warrant
mention. MC innervation is composed of at least two types of C-fibers and both unbranched and branched Aβ-fibers. It is not clear how long the structure of MCs can
persist in the absence of innervation by myelinated and unmyelinated sensory fibers,
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or whether MC structure depends on both or one type of innervation. While the
density of MCs is easily quantifiable with in vivo confocal microscopy, innervation of
the structures cannot be assessed in these images.
Contributions of the disease process to the generation of neuropathy are well
documented as overt clinical signs secondary to the plasma cell dyscrasia (particularly
in POEMS syndrome), or the result of compression of the nerve roots,
cryoglobulinemia or light chain deposits from amyloidosis 102,127. Amyloidosis refers to
precipitation of normally soluble protein due to abnormal folding. The most common
type of amyloidosis is light-chain amyloidosis (AL) and is associated with multiple
myeloma. In AL, light chains become unstable and self-aggregate forming amyloid
fibrils in tissues. This can lead to painful, bilateral sensory neuropathy with progressive
motor involvement 128. POEMS is an acronym that stands for polyneuropathy,
organomegaly, endocrinopathy, M-protein, and skin abnormalities and refers to a rare
monoclonal plasmaproliferative disorder associated with osteosclerotic myeloma 129.
Similar to MM, POEMS patients have monoclonal light chains or immunoglobulins in
their serum, urine, or bone marrow, and typically suffer from a symmetrical neuropathy
due to demyelination and axonal loss of primary afferents 130. The development of
neuropathy in POEMS patients may be due to the secretion of cytokines (e.g. vascular
endothelial growth factor (VEGF), IL-6, and TNF-α) from abnormal plasma cells and
plasmacytomas 131. A similar mechanism may be driving the neuropathy in multiple
myeloma patients. In support of this perspective, MM typically show elevated plasma
cytokines including elevations in TNF-α and IL-6 132,133.
Systemic or perineural administration of TNF-α or IL-6, induces mechanical
allodynia and thermal hyperalgesia 134-137 and an increase in the expression of these
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pro-inflammatory cytokines following nerve injury is observed in and around peripheral
nerves and in the DRG 138-140. Peripheral blockade of pro-inflammatory cytokines
prevents the development of both inflammatory and neuropathic pain. Several
mechanisms by which pro-inflammatory cytokines influence the function of primary
afferent neurons have been described 137,141-145. TNF-α has a rapid, sensitizing effect
on primary afferent neurons resulting in heat-induced CGRP release from nociceptor
terminals in skin and a lowered activation threshold in Aβ- and C-fibers 146-148;
mediated at least in part by sensitization of the TRPV1 and TTX-resistant sodium
channels 149. IL-6 has similarly sensitizing effects on primary afferent fibers through
both its own receptor mediated signaling as well as by potentially inducing TNF-α 150
Kelly et al. suggested that neuropathy associated with disease in myeloma is a
heterogeneous entity resembling carcinomatous neuropathy and that treatment of
myeloma does not affect the course of neuropathy 151. Others have noted that a
number of common disorders of the peripheral nervous system, termed
paraproteinemic neuropathies, are closely connected with the presence of excessive
amounts of an abnormal immunoglobulin in the blood 152. In at least some patients,
these antibodies are directed at components of myelin or the axolemma, resulting in
complement mediated damage to Schwann cells and axons 152. Yet, baseline testing
of colorectal cancer patients with no clinical evidence or reported symptoms of
neuropathy prior to chemotherapy revealed subclinical peripheral neuropathy is a
surprisingly common occurrence (an incidence of 46 of 52 subjects) in this type of
cancer as well 153. This suggests that cancers in general engage biological responses
that impair nerve function. Given the strong connection between pre-existing

59

neuropathy and its exacerbation by disease treatment, these findings underscore the
need for careful screening and individualized treatment plans for patients at risk.
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3. Preliminary analysis of a phase I study of minocycline vs. placebo to prevent
treatment-induced neuropathy in multiple myeloma
3.1.

Introduction

To address Hypothesis 2 of this thesis, the goal of this section was to investigate
whether the antibiotic, minocycline, administered orally during the course of
bortezomib treatment, would prevent sensory neuropathy induced by bortezomib and
decrease patient-reported symptoms of neuropathy. Below is an overview of
minocycline and its potential utility in preventing or treating neuropathic pain and
neurodegenerative disorders.
Neuropathic pain is a catch-all description for a spectrum of abnormal sensory
symptoms that arise due to peripheral or central nervous system damage and can
affect diverse areas of the body depending on the underlying root cause 45. As
discussed in Chapter 1, CIPN is a side-effect of chemotherapy that interferes with
quality of life for patients and compels providers to scale back chemotherapeutic dose.
Neuropathic pain conditions, including CIPN, are often chronic and debilitating medical
conditions that are either incompletely managed by, or refractory to opioids and
medications purposed to treat neuropathic pain (e.g. gabapentin and pregabalin) 154.
Chemotherapy is a scheduled, non-emergency treatment. The most efficient
treatments for CIPN will be preventative measures, rather than reactive medications to
treat already established symptoms of neuropathy. The search for more efficacious
treatments with improved side effect profiles is warranted.
Minocycline is an FDA-approved tetracycline-derived antibiotic predominately
used in the treatment of acne vulgaris. Minocycline is part of a larger class of
tetracyclines, considered broad-spectrum antibiotics effective in eradicating both gram61

positive and gram-negative bacteria. Tetracyclines interfere with bacterial protein
production by binding to the bacterial 30S ribosome subunit and inhibiting translation
of mRNA into polypeptide chains 155. Minocycline is a second-generation tetracycline,
chemically engineered to have increased absorption and bioavailability due its
lipophilic properties and effectively crosses the blood-brain barrier 156. In addition to
well-documented efficacy as an antibiotic, there is a large body of literature that
indicates that minocycline can be used to treat an array of diseases and conditions
through its diverse properties. In the past twenty years, minocycline has been shown
to have anti-inflammatory, immunomodulatory, and neuroprotective effects in both
clinical and pre-clinical studies that suggest a potential therapeutic effect in the
treatment of rheumatoid arthritis, ischemia, aortic aneurysms, cancer metastasis,
traumatic brain injury, spinal cord injury, Parkinson’s disease, Huntington’s disease,
multiple sclerosis and neuropathic pain, among others.155. The neuroprotective
properties of minocycline have been attributed to cellular actions, including the ability
to inhibit microglial activation, microglia-induced release of pro-inflammatory cytokines,
apoptosis, as well as its anti-oxidant properties 157. In rodent models of CIPN, pretreatment with minocycline attenuates hypersensitivity, prevents the loss of
intraepidemal nerve fibers, the activation of astrocytes and the downregulation of
astroglial glutamate transporters, GLAST and GLT-1. Furthermore, the use of
minocycline as a neuroprotective agent has yielded favorable results in several clinical
studies with minimal adverse events 158,159. Spinal cord injury patients treated with
minocycline showed improvement in motor performance in a phase II placebocontrolled randomized trial, though statistical significance was not achieved 160. Preclinical literature indicates that minocycline can prevent the onset of neuropathic pain,
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but cannot reverse pre-established neuropathic pain, making its application ideal as a
preventative treatment 161. These findings, combined with its success in preventing the
development of CIPN in rodents 162,163 suggests that minocycline may be an attractive
candidate for use in the clinical treatment of CIPN.
As previously discussed in section 1.4, treatment of multiple myeloma with the
frontline-chemotherapeutic agent, bortezomib, causes dose-dependent sensory
neuropathy as a side-effect 86. Bortezomib-induced neuropathy (BIPN) causes
discomfort and more importantly, frequent dose reductions, which limit its anti-cancer
efficacy. Bortezomib-treated patients show impairments in Aβ-, Aδ-, and C-primary
afferent subtypes by QST 109. These clinical findings complement the changes seen in
the primary afferent neurons, DRG and spinal cord of bortezomib-treated rodents 90.
Changes in sensory ganglia neurons due to bortezomib include nucleolar hypertrophy,
upregulation of rRNA synthesis, damage of mitochondria and recruitment of satellite
glial cells 90,164. The literature presents mixed findings about the duration and
reversibility of clinical BIPN. Some studies report median times to improvement of
neuropathy grade to be 3 to 4 months for grade 1 or 2 neuropathy and 8 months for
grade 3 or 4 neuropathy 165. Other quantitative studies report BIPN-induced sensory
deficits that are detectable as far as one year following treatment 89. To investigate the
hypothesis that oral minocycline administered with the chemotherapeutic agent,
bortezomib, would prevent sensory neuropathy induced by bortezomib and decrease
patient-reported outcomes of neuropathy, quantitative sensory thresholds and patientreported outcomes were compared to patients randomized to placebo in a doubleblind clinical trial.
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3.2.

Subjects and Methods
3.2.1 Study Site
This study was conducted at the University of Texas MD Anderson Cancer

Center, Houston, TX from March 2011 to October 2013. All enrolled subjects provided
written and oral informed consent and were explained the risks and benefits of
participating in this Phase I protocol as reviewed and approved by the Institutional
Review Board of UT MD Anderson Cancer Center. All subjects signed a written
informed consent before they were enrolled in the study and data was collected.
3.2.2 Study Design
This was a double blind, Phase I, randomized placebo-controlled clinical study to
assess the efficacy of minocycline in preventing bortezomib-induced neuropathy. MM
patients underwent QST (including quantitative and qualitative measures) after
myeloma diagnosis, but prior to beginning chemotherapy as previously described in
Chapter 2. Subjects were then randomized to receive either minocycline 200 mg, or
placebo orally for the first dose, and then 100 mg twice a day for the next ten weeks.
Patients were counseled on accountability and willingness to comply with taking the
study drug as prescribed. The study drug was mailed to study participants with
instructions to begin the first dose on the first day of the first cycle of chemotherapy
treatment. A follow-up quantitative sensory testing was performed on patients during
the course of chemotherapy and minocycline/placebo treatment. The primary endpoint
of this study was fingertip touch detection threshold.
3.2.3 Randomization and Blinding
Study participants were registered in the institutional database Clinical Oncology
Research system (CORe) and randomized to receive placebo or minocycline. This
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information was provided to the institutional pharmacy for disbursement to study
participants. Pharmacy personnel did not interact with personnel collecting the data or
with healthcare providers and were separated by space and department. The
pharmacy maintained records of the randomization list. After seventy-two patients
were enrolled, the randomization list was provided to the institutional statistical
department for analysis.
3.2.4 Inclusion and Exclusion Criteria
Study inclusion criteria were men and women greater than 18 years of age newly
diagnosed with symptomatic MM, having previously received no chemotherapeutic
treatment, but scheduled to receive bortezomib as part of induction therapy for their
disease. Additionally, included patients exhibited no symptoms of neuropathy at
baseline as per physician’s clinical assessment, and pre-menopausal female patients
were willing to use adequate birth control for the duration of the study. Patients were
also required to read and speak English. Patients with a documented allergy to
tetracycline, history of poorly controlled or advanced diabetes mellitus (lab value HA1c
≥ 8%), signs and symptoms of progressive or uncontrolled renal, hepatic,
gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease
documented, peripheral neuropathy of ≥ grade 2 by CTCAE Version 4.0 as per
treating physician, history of malignancy other than MM or a history in the last 5 years,
and significant drug or alcohol use as per social history clinic notes were not
approached for consent.
3.2.5 Protocol Deviations
Deviations from the protocol include individuals who consented to the study, but
had already begun induction therapy and therefore did not provide a baseline test.
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Furthermore, these same individuals were administered the first dose of minocycline
or placebo after induction of chemotherapy.
3.2.6 Clinical Outcome Measures and Methods
Sensory function was assessed by QST on three skin sites: fingertip, thenar
eminence and volar forearm. The primary study endpoint was the touch threshold of
the fingertip. All QST data was collected by research coordinators blind to study group
and experimental design. Sensory testing assessing skin temperature, touch detection
(von Frey and Bumps test), temperature threshold (detection of warm, cool, noxious
heat, and noxious cold), and sharp detection were performed on three skin sites:
fingertip, palm and forearm and a sensorimotor pegboard task was administered as
described in Chapter 2. Patient-reported outcomes were also assessed.
3.2.7 Safety and Tolerability
Previous studies evaluating the safety of 200 mg/day oral minocycline reported no
major concerns and an adverse event profile similar to the placebo group 166. Adverse
events were monitored continuously throughout the study and several patients
discontinued the study drug.
3.2.8 Statistics
All analyses were performed using GraphPad Software, Inc. (La Jolla, CA).
Fisher’s exact test was performed to compare frequency distribution for categorical
variables. Continuous variables (QST measures) were compared between placebo
and minocycline groups with the Kruskall Wallis test (the non-parametric equivalent of
the one-way ANOVA). To compare patients’ initial with follow-up QST, the paired onparametric Wilcoxon-rank sum test was used. No adjustment was made for performing
multiple tests, as this was an exploratory study. Due to the complexity of the data set
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the UT MD Anderson Department of Biostatistics was consulted to perform additional
analyses. These included a backward stepwise regression approach to select
variables to include in a multivariable analysis. The results of the multivariable analysis
can be found in Chapter 5, Appendix B.
3.2.9 Ethics
This study was approved by the Internal Review Board of UT MD Anderson
Cancer Center and conducted in accordance with the principles of the Declaration of
Helsinki and the Guidelines of Good Clinical Practice.
3.3.

Results
3.3.1 Patient Population Analyzed
A total of 72 patients met the inclusion criteria of the study, signed the necessary

informed consent documents and completed at least one QST. Follow-up tests (tests
conducted after baseline) were administered after chemotherapy treatment was
initiated, when patients returned to the hospital for their necessary clinic appointments.
Although this testing schedule was the most convenient option for patient schedules,
patients had different cumulative doses of bortezomib at the time of testing.
Bortezomib was typically administered to patients on days 1, 4, 7, and 11 of a 21-day
cycle at a dose of 1.3 mg/m2, but some patients received a modified version of the
standard dosing due to advanced age, the development of neuropathy, or the use of
adjunctive agents. Bortezomib-induced neuropathy literature suggests that the
development of neuropathy in patients is most likely dose-dependent in nature, with
symptoms worsening as cumulative dose increases 86. Therefore, the cumulative dose
of bortezomib (in total milligrams) at each test for each patient was calculated to
standardize the analysis. Over the course of the study, patients were tested at
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cumulative bortezomib doses ranging from 0 mg to 53.8 mg. Due to the variability in
cumulative dose and number of days between the start of bortezomib and the study
drug (minocycline or placebo), the approach taken in this analysis was to first analyze
a subset of the patients that met all of the initial inclusion criteria for the study
(including a baseline test) and subsequently, to expand the analysis to include a
greater number of patients. Preliminary analysis of primary endpoints did not reach
statistical significance and the study was then closed to future patient entry.
Patient inclusion is depicted in Figure 14. Of the 72 patients initially enrolled in
the study, three patients were removed upon patient request. Two patients were
removed prior to completion due to adverse events. Of these, the first patient was
disenrolled after 24 days of taking the study drug due to high liver function enzymes; at
the conclusion of the study, the patient was found to be in the placebo group,
indicating that high liver function enzymes was unrelated to the study drug. The other
patient was disenrolled after two weeks of taking the study drug due to the
development of a rash. This patient was also in the placebo group. Two additional
placebo patients discontinued the medication for four days or less during the study due
to a presumed allergic reaction. Only one of these patients was included in the final
analysis.
Nineteen patients received a baseline test prior to the start of bortezomib and a
follow-up test during bortezomib treatment. These patients were used for the initial
analysis. A second analysis was performed by grouping 32 patients with a low dose of
chemotherapy with the 19 patients who had received a baseline test for a total of 51
patients. The patients excluded from this analysis lacked an initial test at <13 mg
bortezomib or a follow-up test at >13 mg bortezomib.
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Figure 14 Study Design
Flow-chart of patients excluded or included in the analysis.
3.3.2 Analysis #1
3.3.2.1

Patient Demographics

The first group of patients analyzed (N=19; Placebo: n= 9, Minocycline: n=10) all
received a “true” baseline test (prior to the start of chemotherapy), began taking the
study drug (placebo or minocycline) no later than a week after induction
chemotherapy, and received a follow-up test at cumulative doses in the range of 14.0
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mg to 52.8 mg. A cumulative dose of 14.0 mg roughly corresponds to greater than 1.5
cycles of bortezomib. Due to the already limited sample size, 14.0 was arbitrarily
chosen as the smallest cumulative dose bortezomib at follow-up test to maximize
inclusion of patients. Differences in demographic variables were assessed with the
non-parametric Mann Whitney test for continuous variables or Fisher’s exact test for
discrete variables. Age, sex, and cumulative dose at follow-up test were not
significantly different between the two groups. The minocycline group had significantly
more patients who had undergone radiation treatment prior to their baseline test.
Radiation treatment has the potential of damaging peripheral nerves, although
symptoms of damage often surface years after treatment 167. Because these patients
had received radiation therapy just prior to the baseline test and because baseline
QST did not significantly differ between the two groups, it was considered reasonable
to proceed with the analysis.
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Table 4 Patient Demographics: Analysis #1
Median patient age and cumulative dose were similar between placebo (n=9) and
minocycline (n=10) groups. The numbers of females and males did not differ between
minocycline and placebo groups, however, significantly more patients in the
minocycline group had received prior radiation treatment.
*=P<0.05
Each of the groups (placebo and minocycline) received a baseline test and a
follow-up test during concurrent study drug administration and bortezomib treatment
(≥13 mg). The analysis consisted of four groups: (placebo at baseline (placebobaseline), placebo-post-chemotherapy (placebo-post-chemo), minocycline at baseline
(minocycline-baseline), and minocycline-post-chemotherapy (minocycline-post
chemo). Intragroup comparisons (between placebo-baseline and placebo-post-chemo;
minocycline-baseline and minocycline-post-chemo) were performed with the paired
non-parametric Wilcoxon-rank sum test. Intergroup comparisons (between placebopost-chemo and minocycline-post-chemo) were performed with the non-parametric
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Kruskal-Wallis test. The minocycline-post-chemo and placebo-post-chemo groups
were denoted with the word “max” in all graphs in this analysis.
3.3.2.2

Touch Detection

To assess Aβ-fiber function, mechanical sensitivity of patients was tested. Touch
detection measured with von Frey monofilaments at the volar forearm was significantly
higher in the placebo group post-chemo treatment (0.33±0.10g at baseline versus
0.73±0.21g post-chemo, P=0.03) (Figure 15A), indicating a reduction in tactile
perception at this site. No significant differences were observed at the fingertip or
thenar eminence, or between the other groups. The Bumps detection test measures
fine tactile discrimination of the fingertip. No significant differences were observed in
Bumps detection thresholds of placebo and minocycline groups at either baseline or
post-chemo (Figure 15B). A comparison of baseline versus post-chemo for both von
Frey touch detection and Bumps detection tests suggests that bortezomib does not
alter fine tactile discrimination in placebo-treated MM patients.
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Figure 15 Touch and Bumps Detection Thresholds Showed Few Differences
Between Minocycline and Placebo Groups
(A) Touch threshold measured with von Frey monofilaments at the fingertip, thenar
eminence and volar forearm for the placebo group (black bars) and the minocycline
group (gray bars) at baseline (0 mg) and post-chemotherapy treatment (Max). Touch
threshold in the placebo group significantly increased at the volar forearm after
chemotherapy, but did not differ between any other groups at any other sites. (B) Fine
tactile discrimination of the fingertip assessed with the Bumps detection test. No
significant differences were observed.
*= P<0.05
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3.3.2.3

Peg Board Completion, Sharpness Detection and Skin
Temperature

The peg board completion task assessed dexterity by measuring the latency for
subjects to fit odd-shaped pegs into corresponding holes in a board. The minocycline
group exhibited significantly faster completion of the pegboard with the dominant hand
after bortezomib treatment (75.5±4.9 s) compared with their baseline test (84.6±4.5 s)
(P=0.01) (Figure 16A). However, completion times did not differ significantly between
the minocycline group post-chemo and the placebo group post-chemo. Completion
times for the non-dominant hand did not differ within or between groups.
No significant differences were observed in the sharpness detection test or in skin
temperature (Figure 16B&C).
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Figure 16 Minocycline Group Showed Faster Dominant Hand Peg Board
Completion, but No Differences in Sharpness Detection and Skin Temperature
(A) The time to fit pegs in a pegboard for placebo (black bars) and minocycline (gray
bars) groups. The minocycline group had significantly faster completion times after
bortezomib (P=0.01), but there was no significant difference between the minocycline
and placebo groups post-chemotherapy treatment (Max). (B) Sharpness detection was
assessed (C) Skin temperature was measured. No significant differences were
observed in sharpness detection or skin temperature.
*=P<0.05
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3.3.2.4

Temperature Detection

For temperature detection, patients reported the first detection of a change in the
temperature of a probe (“cool” or “warm”) and then, when the temperature became
painfully cold or hot as a measure of both C- and Aδ-fiber function. The temperature at
which subjects first reported feeling “cool” significantly increased for both placebo
(24.54±2.40 °C) and minocycline (24.55±0.83 °C) groups post-chemotherapy as
compared to respective baseline tests (22.04±0.78 °C and 22.99±0.84 °C, P= 0.03 and
P=0.04) at the fingertip (Figure 17A). However, there was no difference in the cool
fingertip threshold of placebo-post-chemo and minocycline-post-chemo. This suggests
that an increased ability to detect cool is not impacted by treatment with minocycline.
The inverse was seen at the thenar eminence and volar forearm. At both the thenar
eminence and volar forearm, ability to detect cool decreased in the placebo-postchemo group. The threshold at the thenar eminence in the placebo-post-chemo group
was 15.18±1.60 °C, which was significantly lower than 26.08±0.81°C in the placebo
group at baseline (P=0.004) and 24.49±1.25 °C in the minocycline-post-chemo group
(P<0.01). The threshold at the volar forearm for the placebo-post-chemo group was
14.24±2.22 °C, which was significantly lower than the placebo group at baseline
(25.12±0.77 °C, P=0.004) and the minocycline-post-chemo (23.10±1.50 °C, P<0.01).
These data suggest the placebo group was less able to detect cool temperatures after
chemotherapy treatment at the volar forearm and that minocycline may preserve cool
detection at these sites.
Cold pain threshold increased significantly at the fingertip and thenar eminence in
the minocycline-post-chemo group as compared with the minocycline-baseline group,
9.77±2.46 vs. 6.54±1.76 (P=0.002), respectively, at the fingertip and 14.98±2.57 vs.
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13±2.57 (P=0.048), respectively, at the thenar eminence) (Figure 17B). No other
significant differences were observed in cold pain thresholds. The patterns in cool
detection would have been expected if the minocycline had a neuroprotective effect.
However, the minocycline-post chemo group showed increases in cold pain that do not
support a neuroprotective role of minocycline in nociceptive cold fibers.
Bortezomib-induced peripheral neuropathy is thought to affect C-fibers controlling
warm and heat pain 89,109 therefore, these modalities were assessed with a Peltier
thermode (Chapter 2, Figure 7). No significant differences were observed within or
between any groups in warmth detection and heat pain thresholds (Figure 18A&B).

77

Figure 17 Minocycline and Placebo Groups Exhibit Differences in Cool
Detection, and Minocycline Does not Attenuate Increases in Cold Pain
Thresholds
(A) Cool detection threshold measured at the fingertip, thenar eminence and volar
forearm for the placebo group (black bars) and the minocycline group (gray bars). Cool
detection threshold in the placebo and minocycline groups significantly increased at
the fingertip after chemotherapy, but did not differ between any other groups. At the
palm and forearm, the cool threshold was significantly lower in the placebo group after
chemotherapy indicating less ability to discriminate cold. (B) Cold pain threshold
increased at the fingertip and palm in the minocycline group after chemotherapy. No
differences in cold pain at the volar forearm were noted.
*= P<0.05, **=P<0.01
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Figure 18 Warmth and Heat Pain Thresholds Were Not Different Between
Minocycline and Placebo Groups
(A) Warmth detection threshold measured at the fingertip, thenar eminence and volar
forearm for the placebo group (black bars) and the minocycline group (gray bars). (B)
Heat pain thresholds were measured at the same sites. No significant differences were
found in warmth detection or heat pain thresholds.
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3.3.2.5

Rationale for Performing Analysis #2

The pilot study was not suggestive of any conclusive trend regarding the impact of
bortezomib on QST with or without minocycline. Due to the small sample size, it was
decided to utilize less stringent inclusion criteria to expand the number of patients
analyzed. Thirty-two of 72 patients did not have a baseline test prior to beginning
chemotherapy treatment, but did have a test performed at a low dose of bortezomib
(less than 13 mg of bortezomib) and a follow-up test performed during course of
treatment with bortezomib. These patients were added to the previously analyzed
group for a total of 24 patients randomized to receive placebo and 27 to receive
minocycline. First, it was important to determine whether it was appropriate to combine
the QSTs of patients at a true baseline with QSTs of patients at a low initial dose of
bortezomib. To assess this, QSTs of patients randomized to placebo with a true
baseline were compared to those at a low dose of chemotherapy for all tests (e.g.:
Bumps, touch, and temperature detection, etc.) at all sites (e.g.: fingertip, palm,
forearm) using the non-parametric Mann-Whitney test. Although none of the
comparisons were statistically significant, the Bumps test approached statistical
significance with a mean Bumps detection threshold of 4.5±0.71 µm in the placebobaseline group versus 7.28±0.94 µm in the placebo group with a low initial cumulative
dose bortezomib (P=0.07, Figure 19A). The increase in Bumps detection threshold in
the placebo group with a low dose of bortezomib could not solely be explained by the
infusion of chemotherapy because the age of the two groups also approached a
statistically significant difference (placebo: 56±2.39 years, low-dose: 62.13±1.96 years,
P=0.07, Figure 19B). Fine tactile discrimination decreases with age 126,168; therefore,
these differences could have been age-related rather than due to bortezomib infusion .
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In addition, no difference in Bumps detection was observed in the previous analysis in
the placebo group before and after chemotherapy (Figure 15B). Therefore, it was
deemed appropriate to group together the patients with a low dose of chemotherapy
and the patients with a baseline to compare initial and follow-up QSTs. QST tests were
compared as described above using the nonparametric Wilcoxon matched-pairs test
within groups (e.g.: placebo-initial versus placebo-follow-up ) and the non-parametric
Kruskal-Wallis test between groups (e.g.: placebo-follow-up versus minocycline-followup).
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Figure 19 Bumps Detection and Age of Placebo Groups Approach, But Do Not
Reach Statistical Significance Between Placebo 0mg Versus Low-Dose
Low
Bortezomib
(A) Bumps detection and (B) Age
ge of the placebo group prior to chemotherapy
chemother
(black
bars) versus placebo low dose bortezomib group (dotted bars) both approached
(P=0.07),, but did not reach statistical significance.
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3.3.3 Analysis # 2
3.3.3.1

Patient Demographics

A total of 51 patients were analyzed in the subsequent analysis expanded to
include patients with an initial test performed at a low initial dose of bortezomib, and a
follow-up test at a higher cumulative dose bortezomib. The median age of the placebo
group (n=24) and minocycline (n=27) group was 61.5 and 58 years old, respectively
(P=0.79). Sex, previous radiation treatment and cumulative dose of bortezomib at
follow-up test were not different between the two (Table 3.2).

Table 5 Patient Demographics: Analysis #2
Median patient age and cumulative dose were similar between placebo (n=24) and
minocycline (n=27) groups. The numbers of females vs. males and the number of
patients who had received prior radiation were also similar between minocycline and
placebo groups.
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3.3.3.2

Touch Detection

No significant differences were observed in fingertip and thenar eminence touch
detection using von Frey filaments (Figure 20A). Touch detection threshold at the volar
forearm was significantly lower in the minocycline group at follow-up as compared with
their initial test (0.44±0.05 g vs. 0.52±0.02 g, P=0.01). Lower thresholds indicate better
touch detection. Interestingly, the touch threshold at this site was not significantly
different between the two follow-up groups (minocycline and placebo). Similarly,
Bumps detection threshold was significantly higher in the minocycline-follow-up group
as compared to their initial test (minocycline-follow-up: 7.14±0.84 vs. minocyclineinitial: 5.80± 0.74, P=0.03) (Figure 20B), indicating worsening fine tactile
discrimination. Bumps detection for minocycline-follow-up group was not significantly
different from the placebo-follow-up group.
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Figure 20 Touch Detection at Volar Forearm Improved and Bumps Detection at
the Fingertip Worsened in the Minocycline-Follow-Up Group
(A) Touch threshold was measured with von Frey monofilaments at the fingertip,
thenar eminence and volar forearm for the placebo group (black bars) and the
minocycline group (gray bars). Touch threshold in the minocycline group significantly
decreased at the volar forearm after chemotherapy, but did not differ between any
other groups at any other sites. (B) Bumps detection threshold. Fine tactile
discrimination of the fingertip significantly increased in the minocycline follow-up
group.
*= P<0.05
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3.3.3.3

Peg Board Completion, Sharpness Detection and Skin
Temperature

The completion time for peg board was significantly shorter in the minocyclinefollow-up group as compared to their initial test (follow-up: 78.71±3.57 s vs. initial:
83.45±3.52 s) (Figure 21A). There were no differences in sharpness detection and
skin temperature between any of the groups (Figure 21B&C).
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Figure 21 Peg Board Completion, Sharpness Detection, and Skin Temperature
(A) The latency to fit pegs in a pegboard was compared between placebo (black bars)
and minocycline (gray bars) groups. The minocycline-follow-up group had significantly
faster completion times compared to minocycline-baseline (P<0.05), but there was no
significant difference between minocycline-follow-up and placebo-follow-up groups. (B)
Sharpness detection was assessed. (C) Skin temperature was measured. No
significant differences were observed in sharpness detection or skin temperature.
*=P<0.05
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3.3.3.4

Temperature Detection

The temperature for detecting “cool” was not significantly different between the
placebo and minocycline groups at follow-up test, however, both groups had cool
detection thresholds that were significantly higher in temperature when compared to
respective initial tests (placebo-follow-up: 24.02±0.63 °C, placebo-initial: 21.89±0.56
°C, P=0.007) and (minocycline-follow-up: 24.21±0.46 °C, minocycline-initial:
22.69±0.50 °C, P=0.003) (Figure 22A). Cool threshold at the volar forearm was
significantly higher in the placebo-follow-up group compared to the initial test (placebofollow-up: 25.81±0.31°C vs. placebo-initial: 24.43±0.56°C, P=0.03) (Figure 22A). There
were no significant differences in the cool threshold at the thenar eminence.
Cold pain thresholds were parallel to cool thresholds. The cold pain fingertip
thresholds in both minocycline and placebo groups at follow-up were significantly
higher than respective initial tests (placebo-follow-up: 12.57±1.57 °C vs. placeboinitial: 7.39±1.27 °C, P=0.005 and minocycline-follow-up: 9.77±1.23 °C vs. 7.18±1.05
°C minocycline-initial, P=0.003) (Figure 22B). There were no significant differences in
cold pain at the thenar eminence and volar forearm (Figure 22B).
There were no significant differences in warm detection thresholds at any site
(Figure 23A).
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Figure 22 Fingertip Cool and Cold Pain Thresholds
(A) Cool detection threshold measured at the fingertip, thenar eminence and volar
forearm for the placebo group (black bars) and the minocycline group (gray bars). Cool
detection threshold in the placebo-follow-up and minocycline-follow-up groups
significantly increased at the fingertip compared to their respective initial tests. At the
forearm, the cool threshold was significantly higher in the placebo-follow-up group. No
differences in cool detection were seen at the palm. (B) Cold pain threshold increased
at the fingertip in both placebo and minocycline-follow-up group.
*= P<0.05, **=P<0.01
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Figure 23 Warm and Heat Pain Thresholds
(A) Warmth detection threshold measured at the fingertip, thenar eminence and volar
forearm for the placebo group (black bars) and the minocycline group (gray bars). No
significant differences were found in warmth threshold. (B) Heat pain thresholds
measured at the same sites. Heat pain in the placebo-follow-up group occurred at
significantly lower temperatures than the minocycline-initial group.
*=P<0.05
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3.3.3.5

Patient Reported Symptom Descriptors

Rates in patient-reported tingling and numbness were analyzed. As expected,
initial rates of tingling and/or numbness were not different between minocycline and
placebo groups. At follow-up test, 10 of 27 patients reported tingling and 10 of 27
reported numbness in the minocycline group (Figure 24B&D). In the placebo group 11
of 24 patients reported numbness and 14 of 24 reported tingling (Figure 24A&C).
Rates of tingling were lower in the minocycline-follow-up group compared to placebofollow-up group, but statistical significance was not achieved (P=0.11). Patientreported numbness was not statistically significant between minocycline-follow-up and
placebo-follow-up groups by the Fischer’s exact test. However, placebo group reports
of numbness significantly increased at follow-up with 4 patients reporting tingling at the
initial test compared to 14 at the follow-up test (P=0.007) (Figure 24A). Placebo group
reports of numbness approached a statistically significant increase after bortezomib
treatment (at follow-up) (P=0.06) (Figure 24C). No significant differences were
observed between minocycline-patient reported tingling and numbness at the follow-up
test (Figure 24B&D).
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Figure 24 Patient Descriptors
(A&B) The number of patients in placebo and minocycline groups who reported
numbness (black bars) or did not report numbness (gray bars) during initial and followup tests, respectively. (C&D) Rates of tingling in both groups. Significantly more
placebo patients reported numbness after bortezomib as compared to at the initial test.
No other significant differences were observed.
**=P<0.01
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3.4.

Discussion
The present study describes the sensory function of multiple myeloma patients

treated with chemotherapy, including, but not limited to bortezomib, and randomized to
receive minocycline (200 mg/day for ten weeks) or placebo. The first analysis was
performed on patients, who had received baseline testing before chemotherapy. The
second analysis included additional patients, who received initial testing immediately
following induction therapy with a low cumulative dose of bortezomib. All patients
received a follow-up test during the course of their chemotherapy treatment for
comparison. The hypothesis that co-administration of minocycline with bortezomib
would prevent changes in sensory thresholds induced by bortezomib was not
supported. Although patients randomized to receive oral minocycline with bortezomib
treatment displayed few differences in sensory thresholds as measured with QST,
placebo-treated patients did not develop quantifiable sensory deficits after bortezomib
treatment. The hypothesis that administration of minocycline during chemotherapy
treatment would improve patient-reported outcomes was moderately supported by a
reduction in the rates of tingling and numbness in patients randomized to minocycline,
although statistical significance was not achieved.
Surprisingly, the placebo group in this study showed no overall detectable decline
in sensory function after chemotherapy treatment. The cool detection thresholds of the
palm and forearm in Analysis #1 were the only tests in which the placebo group
displayed a significant decline in sensory perception after chemotherapy treatment
(Figure 17). All other tests either showed no significant differences or improvement of
sensory perception after chemotherapy (Figures 16 and 18-23). Despite the lack of
decline in sensory function by QST, patient reports of tingling in the placebo group
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significantly increased from 16.7% at the initial test to 58.3% at the follow-up test.
Patient-reported rates of numbness approached, but did not reach a statistically
significant difference in the placebo group (P=0.06) (Figure 24B). Patients treated with
placebo throughout the course of bortezomib treatment reported increased tingling and
numbness at the follow-up test, suggesting that they had developed neuropathy.
Despite an increase in patient-reported symptoms consistent with neuropathy, no
differences in sensory thresholds were measured with QST after chemotherapy
treatment. The seeming incongruence between patient-reported and QST data may be
because patients reported symptoms that were present in their distal extremities,
which included hands and feet, but sensory thresholds were only measured in the
hands. Clinicians note that bortezomib-induced neuropathy presents sooner, more
frequently, and more severely in the feet as opposed to the hands (unpublished
observation). Given the short ten-week interval between initial and follow-up testing it
is possible that sensory thresholds in the hands were not yet affected by the
bortezomib treatment. It is also a possible that patient-reported symptoms of
neuropathy precede measurable changes in sensory threshold measured with QST.
There are several other possible explanations for the lack of change in sensory
thresholds in MM patients treated with bortezomib and placebo. First, Analysis #1 was
conducted in a very small set of patients (n=9 in the placebo group) making it difficult
to see reliable changes. Analysis #2 was conducted in larger number of patients, but
the majority of these patients underwent initial testing after a small cumulative dose of
chemotherapy. Treatment-emergent peripheral neuropathy can occur in 21% and 37%
patients given a single dose of 1.0 mg/m2 and 1.3 mg/m2, respectively 85. Therefore,
sensory changes could have already occurred in some patients prior to receiving the
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initial test, making it difficult to detect significant changes at the follow-up test. In fact,
when the baseline test of placebo patients with no prior chemotherapy was compared
to placebo patients with a small cumulative dose of chemotherapy, the Bumps
detection test showed a reduced fine tactile discrimination that approached
significance (P=0.07) (Figure 19A). However, this near-significant difference could not
solely be attributed to chemotherapy treatment because the mean age of the latter
patient group was higher (P=0.07). There is an age-related decline in tactile perception
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, therefore, it remains unclear as to whether this difference in tactile perception was

due to aging of the somatosensory system or to chemotherapeutic treatment.
In addition, literature reports the peak of BIPN symptoms to occur at
approximately the fifth cycle of chemotherapy. The follow-up test conducted on this
group of patients occurred less than 10 weeks after starting treatment, meaning that
most patients were tested prior to the fourth cycle of bortezomib. Previous studies
report that patients tested during, and at a year post-bortezomib show similar
magnitudes of QST deficits 89. The stability and lack of worsening in initial versus
follow-up sensory testing of placebo patients in the present study, together with a lack
of improvement at one year post-treatment may be indicative of “coasting.” Although
typically associated with the platin therapies (e.g. cisplatin and oxaliplatin), coasting
refers to symptoms that develop late, but persist or worsen after the end of therapy.
Another possible explanation for the lack of treatment-emergent differences in the
QSTs of placebo patients is the presence of a disease-related neuropathy. Several
studies acknowledge the existence of these subclinical deficits most likely related to
primary cancer 169. Previous psychophysical studies perhaps fail to report subclinical
sensory deficits in treatment-naïve MM patients due to small sample size 109. Future
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QST studies should focus on distinguishing treatment-related from cancer-related
sensory deficits and should investigate whether sub-clinical deficits are associated
with an increased susceptibility for developing CIPN.
In the spinal nerve ligation (SNL) model of neuropathic pain, minocycline
attenuates mechanical hypersensitivity when administered at post-operative day 1 and
3, but cannot reverse established hypersensitivity when administered at later time
points 161. In the SNL rodent model of neuropathic pain, the activation of microglia is
thought to contribute to the development of mechanical hypersensitivity through the
release of inflammatory cytokines 149. The attenuation of neuropathic pain by
minocycline is hypothesized to be due to its suppressive effects on the activation of
microglia 170. This proposed mechanism of action, however, does not account for
minocycline’s efficacy in preventing neuropathic pain caused by chemotherapy, as
rodents treated with chemotherapy do not show microgliosis 171. In CIPN rodent
models the ability of minocycline to block hypersensitivity is likely related to prevention
of astrocyte proliferation and prevention of a chemotherapy-induced downregulation of
glutamate transporters 171. Other supporting evidence for the use of minocycline as a
neuroprotective agent comes from its antioxidant properties, suppression of
chemokines and their receptors, inhibition of T-cell migration into the CNS, protection
of mitochondria, and promotion of anti-apoptotic and suppression of pro-apoptotic
pathways 157. In the present study, the group treated with minocycline showed no
evidence of improvement in sensory function at the follow-up test conducted during the
course of chemotherapy treatment. Some measures such as pegboard completion
time by the dominant hand suggest significant improvement in patients co-treated with
minocycline and bortezomib compared to their initial tests, however this difference was
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not significantly different from the bortezomib-treated patients and most likely
represents a training effect. Thus, we failed to see reliable differences following
minocycline that would suggest neuroprotective effects. Even if improvement had been
observed, no conclusion could be made due to the lack of effect seen in the placebo
group.
Given the clinical importance of this study in evaluating the potential application
of minocycline in bortezomib-induced neuropathic pain, it was decided to consult the
University of Texas MD Anderson Department of Biostatistics for a more formal
analysis capable of adjusting for the complexities present in the dataset. For a
description of the methods and findings of this analysis see Appendix B.
Limitations to this study were primarily related to the complexities of collecting
prospective clinical data. The most significant limitation was the inability to obtain a
baseline test on the vast majority of patients, which required that two separate
analyses be performed. The first analysis had more restricted inclusion criteria,
thereby limiting the sample size, while the second analysis included more patients, the
majority of whom had already received chemotherapy at the initial test. Chemotherapy
treatment prior to the initial test not only added a confounding factor, it also potentially
diluted the effect of the chemotherapy on sensory function that could be observed at
the follow-up test. Additionally, this subset of patients did not take minocycline at the
start of chemotherapy. Pre-clinical studies indicate that the therapeutic time window for
minocycline is limited to the initiation stage of neuropathic pain development 161. This
could be a contributing factor for the lack of effect seen with minocycline. In addition,
the majority of patients in this study received polymodal chemotherapy: bortezomib, in
combination with lenalidomide, thalidomide, cyclophosphamide, and/or
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dexamethasone. Administration of polymodal therapy likely impacts the development
of neuropathy, and research suggests that bortezomib in combination with thalidomide
or the related analog, lenalidomide, produces lower rates of neuropathy, perhaps due
to anti-inflammatory effects of these drugs 172. Patients also received their follow-up
testing at a large range of doses, which introduced additional variability.
Furthermore, the primary end point of the study was touch detection at the fingertip
site. For this test, von Frey filaments of different forces were applied in an up/down
fashion and the subject indicated when the stimulus was perceived. The recorded
threshold was the force that the subject was able to detect three separate times. The
filaments increase in force logarithmically (instead of linearly), which dramatically
increases the probability that the subject detects the next heaviest filament and may
underestimate potential differences. A lack of significance of the primary endpoint
provoked the early closure of this study, which also limited the sample size.
Given the limitations inherent in the study, future clinical trials investigating the
efficacy of minocycline in preventing bortezomib-induced neuropathy should ensure
that all patients received a baseline test and begin the study medication prior to
induction of chemotherapy. Patients should also be stratified based on the presence of
baseline sensory deficits to ensure that treatment and control groups are balanced and
display similar sensory thresholds at baseline. Quantitative sensory testing should be
performed on the feet in addition to the hands, given that symptoms of bortezomibinduced neuropathy predominate in the lower distal extremities. As mentioned, followup testing in this study was performed approximately ten weeks after the initial testing,
meaning that the majority of patients had not yet completed their fourth cycle of
bortezomib. Given that sensory neuropathy increases with cumulative dose of
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chemotherapy, quantitative testing in future studies should be performed at higher
cumulative doses chemotherapy, which would allow testing of sensory thresholds at
the peak of patient complaints of neuropathy. Lastly, given the potentially promising
effect of minocycline in preventing bortezomib-induced patient reports of tingling and
numbness, future studies should focus on patient-reported outcomes. Symptom quality
as well as distribution on the body would be important aspects to consider.
In summary, this was a preliminary analysis performed on quantitative sensory
data from a double-blinded randomized placebo/controlled study to evaluate the
efficacy of minocycline in the prevention of bortezomib-induced neuropathy. Coadministration of minocycline with bortezomib decreased patient reports of tingling and
numbness, although statistical significance was not achieved. However, patients cotreated with bortezomib and placebo did not experience sensory deficits as measured
by QST compared to initial tests. In addition, co-administration of minocycline and
bortezomib, did not produce measurable improvements as compared to placebo in
sensory thresholds. Thus, the hypothesis that oral minocycline co-administered with
the chemotherapeutic agent, bortezomib, would prevent sensory neuropathy induced
by bortezomib and decrease patient-reported outcomes of neuropathy was only
partially supported with a non-significant decrease of tingling and numbness in
minocycline-treated MM patients after bortezomib. The dearth of patients with a
baseline, inconsistencies in the time course that the study drug was administered, the
use of different regimens of polymodal chemotherapy and variations in the dose at
which the follow-up test was conducted are all inherent flaws with the dataset. The
previous success of minocycline as a neuroprotective agent in clinical and pre-clinical
studies as well as its potential to decrease patient reports of neuropathy in the above
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study indicates that this drug may indeed have an effect in CIPN. The effect of
minocycline on CIPN warrants further investigation in a more carefully controlled
prospective trial.
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4. Overall Discussion and Future Directions
Along with surgery and radiation, chemotherapy is the treatment of choice for
cancer. According to the Center for Disease Control, the number of patients in the
United States receiving chemotherapy is 650,000 annually. During and after their
treatment, many of these patients will develop CIPN, a serious side effect that affects
proper sensory function interfering with daily living and treatment administration. The
studies that are the subject of this thesis focus on the subset of cancer patients
diagnosed with MM prior to and following treatment with the proteasome inhibitor,
bortezomib. The goals of these studies were to quantify changes in sensory thresholds
induced by underlying disease processes of cancer as well as to assess the efficacy of
minocycline in preventing sensory neuropathy.
Given that approximately 10% of MM patients present with overt clinical
neuropathy prior to receiving chemotherapy, it was hypothesized that greater numbers
of MM patients exhibit quantifiable changes in sensory thresholds prior to receiving
chemotherapy. To investigate this hypothesis MM patients underwent QST prior to
having received any chemotherapy treatment and were compared to healthy
volunteers. This is the first study conducted on treatment-naïve MM patients to
quantitatively describe changes in sensory thresholds that are suggestive of
impairments in Aβ-, Aδ-, and C-fiber function. In addition, failure to detect small-sized
bumps in a fine tactile discrimination task was correlated with a decreased density of
touch receptors, MCs, in the skin of MM patients. Thus, prior to treatment with
chemotherapy, MM patients already exhibit impairments in mechanosensation,
thermal sensation, and sensorimotor tasks and decreased densities of touch
receptors. These findings are most likely indicative of the direct or indirect effects of
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the MM disease, which have been reviewed in the literature 173,174. It has been
suggested that the presence of subclinical sensory deficits in patients predisposes
them to develop treatment-emergent peripheral neuropathy. If this is the case, those
patients with disease-related neuropathy may require smaller initial doses of
bortezomib or increased monitoring throughout treatment. Future studies should aim to
establish whether there is a connection between subclinical sensory deficits and
treatment-emergent neuropathy. Specifically, it would be interesting to evaluate
whether those patients with subclinical deficits develop treatment-emergent
neuropathy sooner and whether the manifestation is more severe than those who do
not have subclinical deficits. If a clear link is established, this will be a patient
population who may benefit from the application of preventative therapies.
The second hypothesis explored was that MM patients treated with bortezomib
show chemotherapy-induced deficits in sensory function that can be detected by QST
and reversed with the administration of the preventive therapy, tetracycline antibiotic,
minocycline. Killing cancer by reversibly inhibiting proteasomes and facilitating cell
death by allowing the build-up of toxic levels of proteins seemed like an unlikely cancer
therapy until it proved efficacious and was approved for use in multiple myeloma
patients under the trade name Velcade® (bortezomib) 82. While quite effective at
treating MM, bortezomib does not only selectively destroy cancer cells, but also preys
on non-cancer cells. The somatosensory system is particularly vulnerable to the
effects of bortezomib via its ability induce changes in the DRG, which is unprotected
by the blood-brain barrier. Injury of the somatosensory system by bortezomib is a
toxicity causing neuropathic pain to develop in a glove-and-stocking distribution on
patients and frequently results in dose-reduction or cessation of treatment. The utility
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of bortezomib as a treatment for multiple myeloma is restricted by its damage to the
peripheral nervous system (PNS). Optimization of bortezomib treatment will include
reducing or eliminating the damage to the PNS, thereby eliminating the symptoms of
neuropathic pain in patients.
In the second study, we explored the presence of bortezomib-induced deficits
and described the first double blind, placebo-controlled study investigating minocycline
as preventative agent for bortezomib-induced neuropathy. A preliminary analysis of
QST data from MM patients co-administered placebo and bortezomib showed no
detectable decline in sensory function of the placebo group. However, bortezomib did
increase patient reports of tingling and numbness consistent with neuropathy in the
placebo group. Although statistical significance was not achieved, it appeared that
minocycline may have prevented increases in patient-reported tingling. Difficulties
inherent in the collection of prospective clinical data that resulted in the presence of
confounding factors may have disguised any positive effect of minocycline, making it
difficult to discount the potential therapeutic value of this drug. Therefore, the
neuroprotective effects of minocycline observed in pre-clinical and clinical studies
warrant further investigation in a more thoroughly conducted study.
Despite much investigation, chemotherapy-induced peripheral neuropathy is still
a problem pervasive in cancer patients treated with chemotherapy, few novel agents
have proved effective in pre-clinical studies and of these, no single agent has proved
effective in clinical trials. The failure to develop effective therapies stems from our lack
of understanding of mechanisms underlying bortezomib-induced peripheral
neuropathy and more broadly, CIPN. Understanding the changes chemotherapy
induces in receptor and protein expression in neurons associated with symptoms of
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neuropathy will inform the development of drugs aimed to protect these targets. It is
this gap of knowledge that will most adequately be addressed with animal studies.
Several correlate animal studies will be described in Appendix C as a supplement to
the clinical data previously discussed.
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5. Appendices
5.1.

Appendix A: Central Processing of Pain
The spinal cord and brain comprise the CNS. Primary afferent sensory neurons of

the peripheral nervous system project axons to synapse in the spinal cord (Figure 25).
The spinal cord is composed of central gray matter (containing cell bodies of central
neurons) surrounded by white matter (containing afferent and efferent axons). The
dorsal portion of the gray matter receives sensory afferent input from the periphery,
and the ventral gray sends efferent motor information to the periphery. The central
gray matter is divided into eight distinct areas called laminae I- VIII (Figure 25).
Nociceptive primary afferents (Aδ- and C-fibers) project to secondary neurons located
in laminae I and II of the spinal dorsal horn, which project to the brain in the
spinothalamic tract. In addition, to these nociceptive-specific neurons, wide-dynamicrange neurons (WDRs) are also present in lamina I and receive information about
mechanical stimuli (both nociceptive and non-nociceptive) 13. WDRs are also located
in lamina V and project to the brainstem and thalamus. WDRs in lamina V have
dendrites that extend into laminae I and II and make direct contacts with C-fibers. They
also receive indirect information from C-fibers via interneurons and monosynaptic input
from Aβ- and Aδ-fibers 13. Nociceptive visceral afferents also terminate in lamina V.
Non-nociceptive Aβ-fibers predominately terminate in laminae III and IV and have
topographically organized receptive fields. Finally, some neurons in laminae VII and
VIII may receive ipsilateral and contralateral polysynaptic nociceptive input and
contribute to the sensation of diffuse pain.
When stimulated, primary afferent nociceptors release excitatory (glutamate) and
peptide neurotransmitters that bind to their respective receptors on central neurons.
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Glutamate release from Aδ- and C-fibers produces fast depolarization and action
potentials in dorsal horn neurons 12,175. Peptide neurotransmitters, such as substance
P, are also released by peptidergic C-fibers and produce a slower depolarization than
glutamate in spinal dorsal horn neurons 13. Peptidergic and non-peptidergic
transmitters have different properties and may contribute to different aspects of
synaptic transmission. Non-peptidergic transmitters (e.g.: glutamate) have a more
limited range of action than peptide transmitters due to their reuptake by nerve
terminals or glial cells 13. The lack of a reuptake mechanism for peptide transmitters
means that they will stay longer in the synaptic cleft and activate a larger area of
secondary neurons in the spinal cord. Peptidergic transmitters also work
synergistically with non-peptidergic transmitters by perpetuating their effects.

106

Figure 25 Primary Afferent Neuron Synapses in Dorsal Spinal Cord
Illustration of a hemisected spinal cord with gray matter surrounded by white matter.
Primary afferent fibers in the skin have cell bodies located in the dorsal root ganglion
(DRG) and synapse in an organized fashion on different laminae in the spinal cord.
Unmyelinated C-fibers (black) synapse in laminae II of the spinal dorsal horn on
secondary order nociceptors (red) and wide dynamic range neurons (green). Thinly
myelinated Aδ-fibers (orange) project to lamina I on nociceptive secondary neurons.
Large myelinated Aβ-fibers synapse predominately on WDR neurons in lamina V of
the spinal dorsal horn.
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When an individual sustains a localized tissue injury, that area becomes and
remains tender long after the initial damage. Subsequent stimulation of that area
induces pain even if the magnitude is much lower than the initial damaging stimulus.
This is called hyperalgesia and is caused by the sensitization of nociceptors.
Nociceptors are sensitized when the threshold for activation is lowered; damaged cells
and tissues release substances such as prostaglandin, substance P, acetylcholine,
bradykinin, serotonin and leukotriene, which sensitize nociceptors 43. Although primary
afferents receive sensory information, they are also capable of releasing substances
(e.g., substance P and cGRP) synthesized in the cell body in response to injury 176.
These chemical mediators cause vasodilation and lead to inflammation and the
release of other substances that sensitize nearby primary afferents, in a process
termed axon reflex 176,177. Activation of N-methyl-D-aspartate (NMDA) channels by
glutamate underlies “wind-up” and is one of the mechanisms that produces central
sensitization 56. Wind-up occurs due to the persistent firing of C-fibers after serious
injury. Central sensitization occurs when input from primary afferents provokes spinal
dorsal horn neurons to change expression of certain genes, thereby causing an
intrinsic change in firing patterns and hyperexcitabillity 56. This can lead to the
perception of pain in the absence of stimulation.
Spinal dorsal horn neurons relay pain information to the brain in five ascending
pathways: spinothalamic, spinoreticular, spinomesencephalic, cervicothalamic, and
spinohypothalamic 13. The spinothalamic pathway is the major pain pathway, which
carries axons of contralateral spinal dorsal horn neurons from laminae I, V, VI, and VII
in the anterolateral white matter to the thalamus for further processing. Descending
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inhibitory pathways modulate transmission of pain by inhibiting spinal dorsal horn
neurons and thereby evoking analgesia 178.
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Figure 26 Central Pain Processing
Nociceptive primary afferent neurons (1) relay the sensation of pain to the central
nervous system by synapsing on second order spinal dorsal horn neurons (2). Spinal
dorsal horn neurons decussate and ascend in the spinothalamic tract located in the
contralateral anteriorlateral funiculus (3) to the brain (4).
Reprinted from American Association of Critical Care Nurses (ACCN), Renn C and
Dorsey S. Physiology and Processing of Pain: A Review. Copyright 2005, reprinted
with permission from Wolters Kluwer Health.
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5.2.

Appendix B: Additional Statistical Analysis for Chapter 3
Chapter 3 describes a preliminary analysis of the quantitative sensory data from

a phase II study of minocycline vs. placebo to prevent treatment-induced neuropathy
in multiple myeloma patients. Given the limitations of the analysis performed, the
Department of Biostatistics was consulted and asked to perform a separate analysis in
order to account for the effect of multiple independent variables on the dependent
variable (quantitative sensory measure).
The study design was explained at length, and the statistician was provided with
a spreadsheet populated with de-identified patient data. Sixty of 72 patients received
at least two tests and were included in the analysis. Patients with only one QST were
excluded. The following analysis included more patients than Analysis #2 in Chapter 3
because all patients with two tests were included regardless of whether the initial test
was performed at less than 13 mg of chemotherapy. The same measures as above
were analyzed for the fingertip, thenar eminence and forearm. The dependent variable
in this analysis was either analyzed using the value at the follow-up QST at the
maximum cumulative dose of bortezomib or converted into a difference score by
subtracting the value recorded at the lowest cumulative dose of bortezomib (the initial
test) from the value at the highest cumulative dose of bortezomib (the follow-up test).
Backward stepwise regression approach was used for variable selection of
multivariable analyses. The outcome variable (the dependent variable) was either the
follow-up QST value at the highest cumulative dose or the difference score. The input
variables (independent variables) were study drug (minocycline or placebo), whether
study drug was administered prior to bortezomib treatment (yes or no), myeloma stage
(I, II, or III) and cumulative dose in milligrams. P-values less than 0.05 were
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considered statistically significant and all tests were two-sided. Due to the exploratory
nature of this study, no adjustment of multiple tests was performed. All analyses were
performed using SAS 9.3 (SAS Institute Inc., Cary NC).
Adjusting for cumulative dose, whether the study drug was administered prior to
bortezomib, and multiple myeloma stage, minocycline treatment was significantly
associated with a higher temperature of heat pain detection at the fingertip (P=0.04)
and thenar eminence (P=0.01), and lower temperatures of cool detection at the
fingertip (P=0.04), thenar eminence (P=0.03), and volar forearm (P=0.04). Using the
difference score for QST measurements and adjusting for whether the study drug was
administered prior to chemotherapy and the stage, minocycline was only associated
with a decrease in the temperature of cool detection at the forearm (P=0.02)
Limitations of this analysis include the fact that adjustments for cumulative dose
and whether the study drug was administered prior to chemotherapy were performed
for the total group of patients (N=60) analyzed. However, these adjustments should
have been made separately for the minocycline versus placebo group because it
would be expected that the administration of treatment prior to bortezomib would only
be important for the minocycline group if there were a time-dependent effect of the
drug, but not for placebo. Adjustments for cumulative dose should also have been
adjusted for separately in minocycline vs. placebo groups because if minocycline
impacts QST then it may change a dose-dependent effect of bortezomib on sensory
function.

112

5.3.

Appendix C: Related Preclinical Studies
To complement the clinical studies presented in this thesis, several pre-clinical

studies in animal studies were performed in animal models of chemotherapy-induced
neuropathy. Two additional frontline chemotherapeutic agents that commonly cause
neuropathy were investigated in the following studies.
Prior to investigating peripheral innervation in patients using in vivo confocal
microscopy as explained in Chapter 2, biopsies were collected at skin sites that
depicted symptoms of neuropathy. Skin biopsies from patients treated with
chemotherapy showed reduced numbers of nerve fibers compared to biopsies of
healthy controls. Similar quantifications were performed in rodents treated with
chemotherapy.
Aδ- and C-fibers are subtypes of nerve fibers that originate in the dermis layer of
skin and usually cross the dermal-epidermal junction to terminate in the epidermis as
free nerve endings, called intraepidermal nerve fibers (IENFs) (Figure 27). A hallmark
of many small fiber peripheral neuropathies is a decrease in the density of IENFs 179.
Decreases in IENF density are present in patients with symptomatic bortezomibinduced peripheral neuropathy 89 and in rodent models of paclitaxel- and oxaliplatininduced neuropathic pain 162,163. Loss of IENFs seems to approximately correlate with
symptoms of neuropathy, but it is unclear whether or not their loss is responsible for
the hypersensitivity, pain, dysesthesias or paresthesias felt by patients. If the loss of
IENFs underlies symptoms, the question becomes how missing fibers are able to
produce the uncomfortable symptoms of pain and tingling and why they instead do not
produce numbness. The release of cytokines from injured fibers may be driving
symptoms of neuropathy. Since the loss of IENFs may contribute to symptoms of
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neuropathy, treatments that are able to block development of neuropathy might also
be expected to spare nerve fibers. Based on a recently-published study, monocyte
chemoattractant protein-1 (MCP-1) and its chemokine receptor 2 (CCR2) are involved
in the induction and maintenance of paclitaxel-induced neuropathic pain. Knockdown
of CCR2 with intrathecal siRNA attenuates behavioral sensitivity of rodents after
paclitaxel treatment and has IENF densities similar to vehicle-treated animals (Figure
28) 179.
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Figure 27 Intraepidermal Nerve Fibers in Rodent Skin
In red, IENFs labeled with protein gene product 9.5 (PGP 9.5) and in green, collagen
delineating the dermal-epidermal junction in the foot pad of a normal rat.
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MCP-1
1 Prevents the Loss of IENFs Induced by Paclitaxel
Figure 28 Blockade of MCP
(A) Representative
epresentative images of IENFs (red) in the glabrous hindpaw
indpaw skin of the rats
treated with combinations of nonspecific control peptide IgG (NS/IgG),
(NS/IgG anti-MCP-1
IgG. Co-treatment
treatment with anti
anti-MCP-1 and paclitaxel spared IENFs while control peptide
and paclitaxel-treated
treated animals had significantly lowe
lowerr densities of IENFs. (B) The
quantification of IENFs in each treatment condition.
Reprinted from Journal
al of Pain 14(10), Zhang H, Boyette
Boyette-Davis
s JA, Kosturakis AK, Li
Y, Yoon SY, Walters ET, Dougherty PM, Induction of monocyte chemoattractant
protein-1 (MCP-1)
1) and its receptor CCR2 in primary sensory neurons contributes to
paclitaxel-induced
induced peripheral neur
neuropathy. Copyright 2013, reprinted with permission
from Elsevier.
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Quantification of IENFs is performed on slices of skin tissue co-stained with
protein gene product 9.5 (PGP 9.5) expressed in the cytoplasm of neurons and
collagen. Collagen delineates the dermal epidermal junction and restricts quantification
to epidermal fibers. PGP 9.5 is believed to be a pan neuronal marker for IENFs. Other
markers such as calcitonin gene-related peptide (CGRP) are thought to label the
subset of PGP 9.5 fibers expressing CGRP. Figure 29 shows double staining of PGP
9.5 and CGRP markers and a perfect co-localization of CGRP fibers with PGP. Further
experiments, however, show CGRP positive fibers that lack PGP 9.5 staining at
concentrations normally used for quantification (1:500 and 1:400, respectively) (Figure
30). This provoked the question: is PGP 9.5 really a pan neuronal marker? The
implication of this is that PGP 9.5 may not be a reliable marker for quantifying
neuropathy if is not a pan neuronal marker. Further studies are needed to determine if
there are large populations of nerves unlabeled by PGP 9.5.
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CGRP are Co-Localized
Localized in Intraepidemal Nerve Fibers
F
Figure 29 PGP9.5 and C
CGRP (green) IENFs co-localize
localize (yellow) with PGP 9.5 (red) in the epidermis of rodent
hindpaw footpad.

PGP 9.5

PGP 9.5/CGRP

CGRP

Figure 30 Some CGRP Positive Fibers Do Not Appear to Express PGP9.5
CGRP-expressing
expressing fibers in green and PGP 9.5-expressing fibers in red. Some CGRP
positive fibers (solid arrow) do not cco-localize with PGP 9.5. The unfilled
filled arrow points
to the location where the CGRP positive fiber should have been present.
present
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As described in the discussion of Chapter 2, various cytokines, which include
chemokines, are implicated in various inflammatory and pain states 180,181. The
following study was performed in pre-clinical models to investigate the contribution of
the chemokine, monocyte chemoattractant protein 1 (MCP-1) and its cognate receptor,
CCR2, in several inflammatory and neuropathic pain models. To investigate the role of
CCR2 in pain, the painful-behavioral phenotypes of CCR2 knockout (CCR2-KO)
mouse were compared to those of wildtype mice. Intraplantar injection of formalin and
complete Freund’s adjuvant (CFA) served as acute and chronic inflammatory pain
models, respectively. The neuropathic pain models used were spared nerve injury
(SNI) and chemotherapy (paclitaxel and oxaliplatin).
1% Formalin (10 µl) was unilaterally injected to the hindpaw and licking time was
measured. CCR2-KO mice showed no difference in phase 1 (0-10 minutes) or phase 2
(10-45 minutes) of formalin-induced spontaneous pain (Figure 31).
Complete Freunds Adjuvant (CFA) was injected unilaterally into the hindpaws of
wildtype and CCR2-KO mice and mechanical testing was performed on days 1, 3, 7,
15, 20, and 27 after injection. CCR2-KO mice and wildtype mice showed similar
mechanical allodynia after intraplantar CFA that resolved by Day 27 (Figure 32).
Sural and common peroneal branches of left sciatic nerve were ligated and
transected as described 182. CCR2-KO mice showed similar withdrawal thresholds as
sham mice and significantly less mechanical sensitivity compared to wildtype mice on
post-operative days 7 and 14 (Figure 33).
Paclitaxel (2 mg/kg) was injected intraperitoneally on days 1, 3, 5, 7. Mechanical
withdrawal thresholds were tested at Days 7, 14, and 21. CCR2-KO mice treated with
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paclitaxel showed less mechanical hypersensitivity compared with wildtype mice
(Figure 34).
Oxaliplatin (3mg/kg) was injected intraperitoneally every day for 5 days. CCR2KO mice and wildtype mice showed similar decreases in withdrawal thresholds after
oxaliplatin injection (Figure 35).
Taken together, these data suggest that CCR2 contributes to neuropathic, but not
inflammatory pain. Furthermore, CCR2 is involved in neuropathic pain induced by
spared nerve injury and paclitaxel, but not oxaliplatin. Further studies could investigate
the reasons CCR2 is involved in paclitaxel, but not oxaliplatin-induced neuropathy.
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Figure 31 CCR2-KO
KO Mice Showed No Difference in Formalin
Formalin-Induced
Induced
Spontaneous Pain
Duration of licking time in both phase 1 and phase 2 is simi
similar
lar between wildtype and
CCR2-KO mice after intrap
intraplantar formalin injection.

Figure 32 CCR2-KO
KO Mice Showed No Difference in CFA
CFA-Induced
Induced Allodynia
CCR2-KO
KO mice showed similar mechanical withdrawal thresholds after intraplantar
CFA injection.
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Figure 33 CCR2-KO Mice Showed Less Mechanical Hypersensitivity after Spared
Nerve Injury
Mechanical allodynia was significantly reduced in CCR2-KO mice after spared nerve
injury. * P< 0.05, Two-Way ANOVA with Tukey’s post hoc test.

Figure 34 CCR2- KO Mice Showed Less Mechanical Hypersensitivity after
Paclitaxel Treatment
*P<0.05, Multiple t-test
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Figure 35 CCR2-KO Mice Showed No Reduction in Oxaliplatin-Induced
Mechanical Hypersensitivity
*P< 0.01, Saline CCR2 vs. Oxaliplatin CCR2-KO, Two-Way ANOVA with Tukey’s post
hoc test.
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